

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | |
|---|-----------|--|
| (51) International Patent Classification ⁷ : C12N | A2 | (11) International Publication Number: WO 00/32745 (43) International Publication Date: 8 June 2000 (08.06.00) |
| (21) International Application Number: PCT/US99/28075 (22) International Filing Date: 24 November 1999 (24.11.99) (30) Priority Data: 09/201,458 30 November 1998 (30.11.98) US 09/261,358 3 March 1999 (03.03.99) US (71) Applicant: RESEARCH DEVELOPMENT FOUNDATION [US/US]; 402 North Division Street, Carson City, NV 89703 (US). (72) Inventors: WALKER, David, H.; 22 North Dansby, Galveston, TX 77551 (US). YU, Xue-Jie; 6424 Central City Boulevard, No. 828, Galveston, TX 77551 (US). MCBRIDE, Jere, W.; 9457 Jamaica Beach, Galveston, TX 77554 (US). (74) Agent: WEILER, James, F.; 1 Riverway, Suite 1560, Houston, TX 77056 (US). | | (81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i> |
| (54) Title: HOMOLOGOUS 28-KILODALTON IMMUNODOMINANT PROTEIN GENES OF <i>EHRLICHIA CANIS</i> AND USES THEREOF (57) Abstract The present invention is directed to the cloning, sequencing and expression of homologous immunoreactive 28-kDa protein genes, <i>ECa28-1</i> and <i>ECa28SA3</i> , from a polymorphic multiple gene family of <i>Ehrlichia canis</i> . A complete sequence of another 28-kDa protein gene, <i>ECaSA2</i> , is also provided. Further disclosed is a multigene locus encoding all five homologous 28-kDa protein genes of <i>Ehrlichia canis</i> . Recombinant <i>Ehrlichia canis</i> 28-kDa proteins react with convalescent phase antiserum from an <i>E. canis</i> -infected dog. | | |

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | | | |
|----|--------------------------|----|--|----|--|----|--------------------------|
| AL | Albania | ES | Spain | LS | Lesotho | SI | Slovenia |
| AM | Armenia | FI | Finland | LT | Lithuania | SK | Slovakia |
| AT | Austria | FR | France | LU | Luxembourg | SN | Senegal |
| AU | Australia | GA | Gabon | LV | Latvia | SZ | Swaziland |
| AZ | Azerbaijan | GB | United Kingdom | MC | Monaco | TD | Chad |
| BA | Bosnia and Herzegovina | GE | Georgia | MD | Republic of Moldova | TG | Togo |
| BB | Barbados | GH | Ghana | MG | Madagascar | TJ | Tajikistan |
| BE | Belgium | GN | Guinea | MK | The former Yugoslav Republic of Macedonia | TM | Turkmenistan |
| BF | Burkina Faso | GR | Greece | ML | Mali | TR | Turkey |
| BG | Bulgaria | HU | Hungary | MN | Mongolia | TT | Trinidad and Tobago |
| BJ | Benin | IE | Ireland | MR | Mauritania | UA | Ukraine |
| BR | Brazil | IL | Israel | MW | Malawi | UG | Uganda |
| BY | Belarus | IS | Iceland | MX | Mexico | US | United States of America |
| CA | Canada | IT | Italy | NE | Niger | UZ | Uzbekistan |
| CF | Central African Republic | JP | Japan | NL | Netherlands | VN | Viet Nam |
| CG | Congo | KE | Kenya | NO | Norway | YU | Yugoslavia |
| CH | Switzerland | KG | Kyrgyzstan | NZ | New Zealand | ZW | Zimbabwe |
| CI | Côte d'Ivoire | KP | Democratic People's Republic of Korea | PL | Poland | | |
| CM | Cameroon | KR | Republic of Korea | PT | Portugal | | |
| CN | China | KZ | Kazakstan | RO | Romania | | |
| CU | Cuba | LC | Saint Lucia | RU | Russian Federation | | |
| CZ | Czech Republic | LI | Liechtenstein | SD | Sudan | | |
| DE | Germany | LK | Sri Lanka | SE | Sweden | | |
| DK | Denmark | LR | Liberia | SG | Singapore | | |
| EE | Estonia | | | | | | |

HOMOLOGOUS 28-KILODALTON IMMUNODOMINANT PROTEIN GENES OF *EHRlichia CANIS* AND USES THEREOF

5

BACKGROUND OF THE INVENTION

Field of the Invention

10 The present invention relates generally to the field of molecular biology. More specifically, the present invention relates to molecular cloning and characterization of homologous 28-kDa protein genes in *Ehrlichia canis* and a multigene locus encoding the 28-kDa homologous proteins of *Ehrlichia canis* and uses thereof.

15

Description of the Related Art

 Canine ehrlichiosis, also known as canine tropical pancytopenia, is a tick-borne rickettsial disease of dogs first described in Africa in 1935 and the United States in 1963 (Donatien and
20 Lestoquard, 1935; Ewing, 1963). The disease became better recognized after an epizootic outbreak occurred in United States military dogs during the Vietnam War (Walker *et al.*, 1970)

 The etiologic agent of canine ehrlichiosis is *Ehrlichia canis*, a small, gram-negative, obligate intracellular bacterium which exhibits
25 tropism for mononuclear phagocytes (Nyindo *et al.*, 1971) and is transmitted by the brown dog tick, *Rhipicephalus sanguineus* (Groves *et al.*, 1975). The progression of canine ehrlichiosis occurs in three phases, acute, subclinical and chronic. The acute phase is characterized by fever, anorexia, depression, lymphadenopathy and
30 mild thrombocytopenia (Troy and Forrester, 1990). Dogs typically

recover from the acute phase, but become persistently infected carriers of the organism without clinical signs of disease for months or even years (Harrus *et al.*, 1998). A chronic phase develops in some cases that is characterized by thrombocytopenia, hyperglobulinemia, anorexia, emaciation, and hemorrhage, particularly epistaxis, followed by death (Troy and Forrester, 1990).

Molecular taxonomic analysis based on the 16S rRNA gene has determined that *E. canis* and *E. chaffeensis*, the etiologic agent of human monocytic ehrlichiosis (HME), are closely related (Anderson *et al.*, 1991; Anderson *et al.*, 1992; Dawson *et al.*, 1991; Chen *et al.*, 1994). Considerable cross reactivity of the 64, 47, 40, 30, 29 and 23-kDa antigens between *E. canis* and *E. chaffeensis* has been reported (Chen *et al.*, 1994; Chen *et al.*, 1997; Rikihisa *et al.*, 1994; Rikihisa *et al.*, 1992). Analysis of immunoreactive antigens with human and canine convalescent phase sera by immunoblot has resulted in the identification of numerous immunodominant proteins of *E. canis*, including a 30-kDa protein (Chen *et al.*, 1997). In addition, a 30-kDa protein of *E. canis* has been described as a major immunodominant antigen recognized early in the immune response that is antigenically distinct from the 30-kDa protein of *E. chaffeensis* (Rikihisa *et al.*, 1992; Rikihisa *et al.*, 1994). Other immunodominant proteins of *E. canis* with molecular masses ranging from 20 to 30-kDa have also been identified (Brouqui *et al.*, 1992; Nyindo *et al.*, 1991; Chen *et al.*, 1994; Chen *et al.*, 1997).

Recently, cloning and sequencing of a multigene family (*omp-1*) encoding proteins of 23 to 28-kDa have been described for *E. chaffeensis* (Ohashi *et al.*, 1998). The 28-kDa immunodominant outer membrane protein gene (*p28*) of *E. chaffeensis*, homologous to the *Cowdria ruminantium map-1* gene, was cloned. Mice immunized with recombinant P28 were protected against challenge infection with the

homologous strain according to PCR analysis of peripheral blood 5 days after challenge (Ohashi *et al.*, 1998). Molecular cloning of two similar, but nonidentical, tandemly arranged 28-kDa genes of *E. canis* homologous to *E. chaffeensis omp-1* gene family and *C. rumanintium map-1* gene has also been reported (Reddy *et al.*, 1998).

The prior art is deficient in the lack of cloning and characterization of new homologous 28-kDa immunoreactive protein genes of *Ehrlichia canis* and a single multigene locus containing the homologous 28-kDa protein genes. Further, The prior art is deficient in the lack of recombinant proteins of such immunoreactive genes of *Ehrlichia canis*. The present invention fulfills this long-standing need and desire in the art.

SUMMARY OF THE INVENTION

The present invention describes the molecular cloning, sequencing, characterization, and expression of homologous mature 28-kDa immunoreactive protein genes of *Ehrlichia canis* (designated *Eca28-1*, *ECa28SA3* and *ECa28SA2*), and the identification of a single locus (5.592-kb) containing five 28-kDa protein genes of *Ehrlichia canis* (*ECa28SA1*, *ECa28SA2*, *ECa28SA3*, *Eca28-1* and *ECa28-2*). Comparison with *E. chaffeensis* and among *E. canis* 28-kDa protein genes revealed that *ECa28-1* shares the most amino acid homology with the *E. chaffeensis omp-1* multigene family and is highly conserved among *E. canis* isolates. The five 28-kDa proteins were predicted to have signal peptides resulting in mature proteins, and had amino acid homology ranging from 51 to 72%. Analysis of intergenic regions revealed hypothetical promoter regions for each gene, suggesting that these genes may be independently and differentially expressed. Intergenic noncoding regions ranged in size from 299 to 355-bp, and

were 48 to 71% homologous.

In one embodiment of the present invention, there are provided DNA sequences encoding a 30-kDa immunoreactive protein of *Ehrlichia canis*. Preferably, the protein has an amino acid sequence
5 selected from the group consisting of SEQ ID No. 2, SEQ ID No. 4 and SEQ ID No. 6, and the gene has a nucleic acid sequence selected from the group consisting of SEQ ID No. 1, SEQ ID No. 3 and SEQ ID No. 5 and is a member of a polymorphic multiple gene family. Generally, the protein has an N-terminal signal sequence which is cleaved after
10 post-translational process resulting in the production of a mature 28-kDa protein. Still preferably, the DNAs encoding 28-kDa proteins are contained in a single multigene locus, which has the size of 5.592 kb and encodes all five homologous 28-kDa proteins of *Ehrlichia canis*.

In another embodiment of the present invention, there is
15 provided an expression vector comprising a gene encoding a 28-kDa immunoreactive protein of *Ehrlichia canis* and capable of expressing the gene when the vector is introduced into a cell.

In still another embodiment of the present invention, there is provided a recombinant protein comprising an amino acid sequence
20 selected from the group consisting of SEQ ID No. 2, SEQ ID No. 4 and SEQ ID No. 6. Preferably, the amino acid sequence is encoded by a nucleic acid sequence selected from the group consisting of SEQ ID No. 1, SEQ ID No. 3 and SEQ ID No. 5. Preferably, the recombinant protein comprises four variable regions which are surface exposed,
25 hydrophilic and antigenic. The recombinant protein may be useful as an antigen.

In yet another embodiment of the present invention, there is provided a method of producing the recombinant protein, comprising the steps of obtaining a vector that comprises an
30 expression region comprising a sequence encoding the amino acid

sequence selected from the group consisting of SEQ ID No. 2, SEQ ID No. 4 and SEQ ID No. 6 operatively linked to a promoter; transfecting the vector into a cell; and culturing the cell under conditions effective for expression of the expression region.

5 The invention may also be described in certain embodiments as a method of inhibiting *Ehrlichia canis* infection in a subject comprising the steps of: identifying a subject suspected of being exposed to or infected with *Ehrlichia canis*; and administering a composition comprising a 28-kDa antigen of *Ehrlichia canis* in an
10 amount effective to inhibit an *Ehrlichia canis* infection. The inhibition may occur through any means such as, i.e. the stimulation of the subject's humoral or cellular immune responses, or by other means such as inhibiting the normal function of the 28-kDa antigen, or even competing with the antigen for interaction with some agent in the
15 subject's body.

Other and further aspects, features, and advantages of the present invention will be apparent from the following description of the presently preferred embodiments of the invention given for the purpose of disclosure.

20

BRIEF DESCRIPTION OF THE DRAWINGS

So that the matter in which the above-recited features, advantages and objects of the invention, as well as others which will
25 become clear, are attained and can be understood in detail, more particular descriptions of the invention briefly summarized above may be had by reference to certain embodiments thereof which are illustrated in the appended drawings. These drawings form a part of the specification. It is to be noted, however, that the appended

drawings illustrate preferred embodiments of the invention and therefore are not to be considered limiting in their scope.

Figure 1 shows nucleic acid sequence (SEQ ID No. 1) and deduced amino acid sequence (SEQ ID No. 2) of *ECa28-1* gene including adjacent 5' and 3' non-coding sequences. The ATG start codon and TAA termination are shown in bold, and the 23 amino acid leader signal sequence is underlined.

Figure 2 shows SDS-PAGE of expressed 50-kDa recombinant *ECa28-1*-thioredoxin fusion protein (Lane 1, arrow) and 16-kDa thioredoxin control (Lane 2, arrow), and corresponding immunoblot of recombinant *ECa28-1*-thioredoxin fusion protein recognized by covalent-phase *E. canis* canine antiserum (Lane 3). Thioredoxin control was not detected by *E.canis* antiserum (not shown).

Figure 3 shows alignment of *ECa28-1* protein (SEQ ID NO. 2), and *ECa28SA2* (partial sequence, SEQ ID NO. 7) and *ECa28SA1* (SEQ ID NO. 8), *E. chaffeensis* P28 (SEQ ID NO. 9), *E. chaffeensis* OMP-1 family (SEQ ID NOs: 10-14) and *C. ruminantium* MAP-1 (SEQ ID NO. 15) amino acid sequences. The *ECa28-1* amino acid sequence is presented as the consensus sequence. Amino acids not shown are identical to *ECa28-1* and are represented by a dot. Divergent amino acids are shown with the corresponding one letter abbreviation. Gaps introduced for maximal alignment of the amino acid sequences are denoted with a dash. Variable regions are underlined and denoted (VR1, VR2, VR3, and VR4). The arrows indicate the predicted signal peptidase cleavage site for the signal peptide.

Figure 4 shows phylogenetic relatedness of *E. canis* *ECa28-1* with the *ECa28SA2* (partial sequence) and *ECa28SA1*, 6 members of the *E.chaffeensis omp-1* multiple gene family, and *C. rumanintium map-1* from deduced amino acid sequences utilizing unbalanced tree

construction. The length of each pair of branches represents the distance between the amino acid sequence of the pairs. The scale measures the distance between sequences.

Figure 5 shows Southern blot analysis of *E. canis* genomic DNA completely digested with six individual restriction enzymes and hybridized with a ECa28-1 DIG-labeled probe (Lanes 2-7); DIG-labeled molecular weight markers (Lanes 1 and 8).

Figure 6 shows comparison of predicted protein characteristics of ECa28-1 (Jake strain) and *E. chaffeensis* P28 (Arkansas strain). Surface probability predicts the surface residues by using a window of hexapeptide. A surface residue is any residue with a $>2.0 \text{ nm}^2$ of water accessible surface area. A hexapeptide with a value higher than 1 was considered as surface region. The antigenic index predicts potential antigenic determinants. The regions with a value above zero are potential antigenic determinants. T-cell motif locates the potential T-cell antigenic determinants by using a motif of 5 amino acids with residue 1-glycine or polar, residue 2-hydrophobic, residue 3-hydrophobic, residue 4-hydrophobic or proline, and residue 5-polar or glycine. The scale indicates amino acid positions.

Figure 7 shows nucleic acid sequences and deduced amino acid sequences of the *E. canis* 28-kDa protein genes *ECa28SA2* (nucleotide 1-849: SEQ ID No. 3; amino acid sequence: SEQ ID No. 4) and *ECa28SA3* (nucleotide 1195-2031: SEQ ID No. 5; amino acid sequence: SEQ ID No. 6) including intergenic noncoding sequences (NC2, nucleotide 850-1194: SEQ ID No. 31). The ATG start codon and termination condons are shown in bold.

Figure 8 shows schematic of the five *E. canis* 28-kDa protein gene locus (5.592-Kb) indicating genomic orientation and intergenic noncoding regions (28NC1-4). The 28-kDa protein genes shown in Locus 1 and 2 (shaded) have been described (McBride *et al.*,

1999; Reddy *et al.*, 1998; Ohashi *et al.*, 1998). The complete sequence of *ECaSA2* and a new 28-kDa protein gene designated (*ECa28SA3* - unshaded) was sequenced. The noncoding intergenic regions (28NC2-3) between *ECaSA2*, *ECa28SA3* and *ECa28-1* were completed joining the previously unlinked loci 1 and 2.

Figure 9 shows phylogenetic relatedness of the five *E. canis* 28-kDa protein gene members based on amino acid sequences utilizing unbalanced tree construction. The length of each pair of branches represents the distance between amino acid pairs. The scale measures the distance between sequences.

Figure 10 shows alignment of *E. canis* 28-kDa protein gene intergenic noncoding nucleic acid sequences (SEQ ID Nos. 30-33). Nucleic acids not shown, denoted with a dot (.), are identical to noncoding region 1 (28NC1). Divergence is shown with the corresponding one letter abbreviation. Gaps introduced for maximal alignment of the amino acid sequences are denoted with a dash (-). Putative transcriptional promoter regions (-10 and -35) and ribosomal binding site (RBS) are boxed.

DETAILED DESCRIPTION OF THE INVENTION

The present invention describes cloning, sequencing and expression of homologous genes encoding a 30-kilodalton (kDa) protein of *Ehrlichia canis*. A comparative molecular analysis of homologous genes among seven *E. canis* isolates and the *E. chaffeensis omp-1* multigene family was also performed. Two new 28-kDa protein genes are identified, *ECa28-1* and *ECa28SA3*. *ECa28-1* has an 834-bp open reading frame encoding a protein of 278 amino acids (SEQ ID No. 2) with a predicted molecular mass of 30.5-kDa. An N-terminal signal sequence was identified suggesting that the protein is post-

translationally modified to a mature protein of 27.7-kDa. *ECa28SA3* has an 840-bp open reading frame encoding a 280 amino acid protein (SEQ ID No. 6).

Using PCR to amplify 28-kDa protein genes of *E. canis*, a previously unsequenced region of *Eca28SA2* was completed. Sequence analysis of *ECa28SA2* revealed an 849-bp open reading frame encoding a 283 amino acid protein (SEQ ID No. 4). PCR amplification using primers specific for 28-kDa protein gene intergenic noncoding regions linked two previously separate loci, identifying a single locus (5.592-10 kb) containing all five 28-kDa protein genes. The five 28-kDa proteins were predicted to have signal peptides resulting in mature proteins, and had amino acid homology ranging from 51 to 72%. Analysis of intergenic regions revealed hypothetical promoter regions for each gene, suggesting that these genes may be independently and15 differentially expressed. Intergenic noncoding regions (28NC1-4) ranged in size from 299 to 355-bp, and were 48 to 71% homologous.

The present invention is directed to two new homologous 28-kDa protein genes in *Ehrlichia canis*, *Eca28-1* and *ECa28SA3*, and a complete sequence of previously partially sequenced *ECa28SA2*. Also20 disclosed is a multigene locus encoding all five homologous 28-kDa outer membrane proteins of *Ehrlichia canis*.

In one embodiment of the present invention, there are provided DNA sequences encoding a 30-kDa immunoreactive protein of *Ehrlichia canis*. Preferably, the protein has an amino acid sequence25 selected from the group consisting of SEQ ID No. 2, SEQ ID No. 4 and SEQ ID No. 6, and the gene has a nucleic acid sequence selected from the group consisting of SEQ ID No. 1, SEQ ID No. 3 and SEQ ID No. 5 and is a member of a polymorphic multiple gene family. More preferably, the protein has an N-terminal signal sequence which is30 cleaved after post-translational process resulting in the production of

a mature 28-kDa protein. Still preferably, the DNAs encoding 28-kDa proteins are contained in a single multigene locus, which has the size of 5.592 kb and encodes all five homologous 28-kDa proteins of *Ehrlichia canis*.

5 In another embodiment of the present invention, there is provided an expression vector comprising a gene encoding a 28-kDa immunoreactive protein of *Ehrlichia canis* and capable of expressing the gene when the vector is introduced into a cell.

10 In still another embodiment of the present invention, there is provided a recombinant protein comprising an amino acid sequence selected from the group consisting of SEQ ID No. 2, SEQ ID No. 4 and SEQ ID No. 6. Preferably, the amino acid sequence is encoded by a nucleic acid sequence selected from the group consisting of SEQ ID No. 1, SEQ ID No. 3 and SEQ ID No. 5. Preferably, the recombinant
15 protein comprises four variable regions which are surface exposed, hydrophilic and antigenic. Still preferably, the recombinant protein is an antigen.

In yet another embodiment of the present invention, there is provided a method of producing the recombinant protein,
20 comprising the steps of obtaining a vector that comprises an expression region comprising a sequence encoding the amino acid sequence selected from the group consisting of SEQ ID No. 2, SEQ ID No. 4 and SEQ ID No. 6 operatively linked to a promoter; transfecting the vector into a cell; and culturing the cell under conditions effective
25 for expression of the expression region.

The invention may also be described in certain embodiments as a method of inhibiting *Ehrlichia canis* infection in a subject comprising the steps of: identifying a subject suspected of being exposed to or infected with *Ehrlichia canis*; and administering a
30 composition comprising a 28-kDa antigen of *Ehrlichia canis* in an

amount effective to inhibit an *Ehrlichia canis* infection. The inhibition may occur through any means such as, i.e. the stimulation of the subject's humoral or cellular immune responses, or by other means such as inhibiting the normal function of the 28-kDa antigen, or even
5 competing with the antigen for interaction with some agent in the subject's body.

In accordance with the present invention there may be employed conventional molecular biology, microbiology, and recombinant DNA techniques within the skill of the art. Such
10 techniques are explained fully in the literature. See, e.g., Maniatis, Fritsch & Sambrook, "Molecular Cloning: A Laboratory Manual (1982); "DNA Cloning: A Practical Approach," Volumes I and II (D.N. Glover ed. 1985); "Oligonucleotide Synthesis" (M.J. Gait ed. 1984); "Nucleic Acid Hybridization" [B.D. Hames & S.J. Higgins eds. (1985)]; "Transcription
15 and Translation" [B.D. Hames & S.J. Higgins eds. (1984)]; "Animal Cell Culture" [R.I. Freshney, ed. (1986)]; "Immobilized Cells And Enzymes" [IRL Press, (1986)]; B. Perbal, "A Practical Guide To Molecular Cloning" (1984).

Therefore, if appearing herein, the following terms shall
20 have the definitions set out below.

A "replicon" is any genetic element (e.g., plasmid, chromosome, virus) that functions as an autonomous unit of DNA replication *in vivo*; i.e., capable of replication under its own control.

A "vector" is a replicon, such as plasmid, phage or cosmid,
25 to which another DNA segment may be attached so as to bring about the replication of the attached segment.

A "DNA molecule" refers to the polymeric form of deoxyribonucleotides (adenine, guanine, thymine, or cytosine) in its either single stranded form, or a double-stranded helix. This term
30 refers only to the primary and secondary structure of the molecule,

and does not limit it to any particular tertiary forms. Thus, this term includes double-stranded DNA found, *inter alia*, in linear DNA molecules (e.g., restriction fragments), viruses, plasmids, and chromosomes. In discussing the structure herein according to the
5 normal convention of giving only the sequence in the 5' to 3' direction along the nontranscribed strand of DNA (i.e., the strand having a sequence homologous to the mRNA).

A DNA "coding sequence" is a double-stranded DNA sequence which is transcribed and translated into a polypeptide *in vivo* when placed under the control of appropriate regulatory sequences. The boundaries of the coding sequence are determined by a start codon at the 5' (amino) terminus and a translation stop codon at the 3' (carboxyl) terminus. A coding sequence can include, but is not limited to, prokaryotic sequences, cDNA from eukaryotic mRNA,
10 genomic DNA sequences from eukaryotic (e.g., mammalian) DNA, and even synthetic DNA sequences. A polyadenylation signal and transcription termination sequence will usually be located 3' to the coding sequence.

Transcriptional and translational control sequences are
20 DNA regulatory sequences, such as promoters, enhancers, polyadenylation signals, terminators, and the like, that provide for the expression of a coding sequence in a host cell.

A "promoter sequence" is a DNA regulatory region capable of binding RNA polymerase in a cell and initiating transcription of a
25 downstream (3' direction) coding sequence. For purposes of defining the present invention, the promoter sequence is bounded at its 3' terminus by the transcription initiation site and extends upstream (5' direction) to include the minimum number of bases or elements necessary to initiate transcription at levels detectable above
30 background. Within the promoter sequence will be found a

transcription initiation site, as well as protein binding domains (consensus sequences) responsible for the binding of RNA polymerase. Eukaryotic promoters often, but not always, contain "TATA" boxes and "CAT" boxes. Prokaryotic promoters contain Shine-Dalgarno sequences in addition to the -10 and -35 consensus sequences.

An "expression control sequence" is a DNA sequence that controls and regulates the transcription and translation of another DNA sequence. A coding sequence is "under the control" of transcriptional and translational control sequences in a cell when RNA polymerase transcribes the coding sequence into mRNA, which is then translated into the protein encoded by the coding sequence.

A "signal sequence" can be included near the coding sequence. This sequence encodes a signal peptide, N-terminal to the polypeptide, that communicates to the host cell to direct the polypeptide to the cell surface or secrete the polypeptide into the media, and this signal peptide is clipped off by the host cell before the protein leaves the cell. Signal sequences can be found associated with a variety of proteins native to prokaryotes and eukaryotes.

The term "oligonucleotide", as used herein in referring to the probe of the present invention, is defined as a molecule comprised of two or more ribonucleotides, preferably more than three. Its exact size will depend upon many factors which, in turn, depend upon the ultimate function and use of the oligonucleotide.

The term "primer" as used herein refers to an oligonucleotide, whether occurring naturally as in a purified restriction digest or produced synthetically, which is capable of acting as a point of initiation of synthesis when placed under conditions in which synthesis of a primer extension product, which is complementary to a nucleic acid strand, is induced, i.e., in the

presence of nucleotides and an inducing agent such as a DNA polymerase and at a suitable temperature and pH. The primer may be either single-stranded or double-stranded and must be sufficiently long to prime the synthesis of the desired extension product in the presence of the inducing agent. The exact length of the primer will depend upon many factors, including temperature, source of primer and use the method. For example, for diagnostic applications, depending on the complexity of the target sequence, the oligonucleotide primer typically contains 15-25 or more nucleotides, although it may contain fewer nucleotides.

The primers herein are selected to be "substantially" complementary to different strands of a particular target DNA sequence. This means that the primers must be sufficiently complementary to hybridize with their respective strands. Therefore, the primer sequence need not reflect the exact sequence of the template. For example, a non-complementary nucleotide fragment may be attached to the 5' end of the primer, with the remainder of the primer sequence being complementary to the strand. Alternatively, non-complementary bases or longer sequences can be interspersed into the primer, provided that the primer sequence has sufficient complementarity with the sequence or hybridize therewith and thereby form the template for the synthesis of the extension product.

A cell has been "transformed" by exogenous or heterologous DNA when such DNA has been introduced inside the cell. The transforming DNA may or may not be integrated (covalently linked) into the genome of the cell. In prokaryotes, yeast, and mammalian cells for example, the transforming DNA may be maintained on an episomal element such as a plasmid. With respect to eukaryotic cells, a stably transformed cell is one in which the transforming DNA has become integrated into a chromosome so that

it is inherited by daughter cells through chromosome replication. This stability is demonstrated by the ability of the eukaryotic cell to establish cell lines or clones comprised of a population of daughter cells containing the transforming DNA. A "clone" is a population of
5 cells derived from a single cell or ancestor by mitosis. A "cell line" is a clone of a primary cell that is capable of stable growth *in vitro* for many generations.

Two DNA sequences are "substantially homologous" when at least about 75% (preferably at least about 80%, and most
10 preferably at least about 90% or 95%) of the nucleotides match over the defined length of the DNA sequences. Sequences that are substantially homologous can be identified by comparing the sequences using standard software available in sequence data banks, or in a Southern hybridization experiment under, for example,
15 stringent conditions as defined for that particular system. Defining appropriate hybridization conditions is within the skill of the art. See, e.g., Maniatis et al., *supra*; DNA Cloning, Vols. I & II, *supra*; Nucleic Acid Hybridization, *supra*.

A "heterologous" region of the DNA construct is an
20 identifiable segment of DNA within a larger DNA molecule that is not found in association with the larger molecule in nature. Thus, when the heterologous region encodes a mammalian gene, the gene will usually be flanked by DNA that does not flank the mammalian genomic DNA in the genome of the source organism. In another
25 example, coding sequence is a construct where the coding sequence itself is not found in nature (e.g., a cDNA where the genomic coding sequence contains introns, or synthetic sequences having codons different than the native gene). Allelic variations or naturally-
occurring mutational events do not give rise to a heterologous region
30 of DNA as defined herein.

The labels most commonly employed for these studies are radioactive elements, enzymes, chemicals which fluoresce when exposed to ultraviolet light, and others. A number of fluorescent materials are known and can be utilized as labels. These include, for
5 example, fluorescein, rhodamine, auramine, Texas Red, AMCA blue and Lucifer Yellow. A particular detecting material is anti-rabbit antibody prepared in goats and conjugated with fluorescein through an isothiocyanate.

Proteins can also be labeled with a radioactive element or
10 with an enzyme. The radioactive label can be detected by any of the currently available counting procedures. The preferred isotope may be selected from ^3H , ^{14}C , ^{32}P , ^{35}S , ^{36}Cl , ^{51}Cr , ^{57}Co , ^{58}Co , ^{59}Fe , ^{90}Y , ^{125}I , ^{131}I , and ^{186}Re .

Enzyme labels are likewise useful, and can be detected by
15 any of the presently utilized colorimetric, spectrophotometric, fluorospectrophotometric, amperometric or gasometric techniques. The enzyme is conjugated to the selected particle by reaction with bridging molecules such as carbodiimides, diisocyanates, glutaraldehyde and the like. Many enzymes which can be used in
20 these procedures are known and can be utilized. The preferred are peroxidase, β -glucuronidase, β -D-glucosidase, β -D-galactosidase, urease, glucose oxidase plus peroxidase and alkaline phosphatase. U.S. Patent Nos. 3,654,090, 3,850,752, and 4,016,043 are referred to by way of example for their disclosure of alternate labeling material
25 and methods.

As used herein, the term "host" is meant to include not only prokaryotes but also eukaryotes such as yeast, plant and animal cells. A recombinant DNA molecule or gene which encodes a 28-kDa immunoreactive protein of *Ehrlichia canis* of the present invention can

be used to transform a host using any of the techniques commonly known to those of ordinary skill in the art. Especially preferred is the use of a vector containing coding sequences for a gene encoding a 28-kDa immunoreactive protein of *Ehrlichia canis* of the present invention for purposes of prokaryote transformation.

Prokaryotic hosts may include *E. coli*, *S. typhimurium*, *Serratia marcescens* and *Bacillus subtilis*. Eukaryotic hosts include yeasts such as *Pichia pastoris*, mammalian cells and insect cells.

In general, expression vectors containing promoter sequences which facilitate the efficient transcription of the inserted DNA fragment are used in connection with the host. The expression vector typically contains an origin of replication, promoter(s), terminator(s), as well as specific genes which are capable of providing phenotypic selection in transformed cells. The transformed hosts can be fermented and cultured according to means known in the art to achieve optimal cell growth.

The invention includes a substantially pure DNA encoding a 28-kDa immunoreactive protein of *Ehrlichia canis*, a strand of which DNA will hybridize at high stringency to a probe containing a sequence of at least 15 consecutive nucleotides of SEQ ID No. 1 or SEQ ID No. 3 or SEQ ID No. 5. The protein encoded by the DNA of this invention may share at least 80% sequence identity (preferably 85%, more preferably 90%, and most preferably 95%) with the amino acids listed in SEQ ID No. 2 or SEQ ID No. 4 or SEQ ID No. 6. More preferably, the DNA includes the coding sequence of the nucleotides of SEQ ID No. 1 or SEQ ID No. 3 or SEQ ID No. 5, or a degenerate variant of such a sequence.

The probe to which the DNA of the invention hybridizes preferably consists of a sequence of at least 20 consecutive nucleotides, more preferably 40 nucleotides, even more preferably 50

nucleotides, and most preferably 100 nucleotides or more (up to 100%) of the coding sequence of the nucleotides listed in SEQ ID No. 1 or SEQ ID No. 3 or SEQ ID No. 5 or the complement thereof. Such a probe is useful for detecting expression of the 28-kDa immunoreactive protein of *Ehrlichia canis* in a human cell by a method including the steps of (a) contacting mRNA obtained from the cell with the labeled hybridization probe; and (b) detecting hybridization of the probe with the mRNA.

This invention also includes a substantially pure DNA containing a sequence of at least 15 consecutive nucleotides (preferably 20, more preferably 30, even more preferably 50, and most preferably all) of the region from the nucleotides listed in SEQ ID No 1 or SEQ ID No. 3 or SEQ ID No. 5.

By "high stringency" is meant DNA hybridization and wash conditions characterized by high temperature and low salt concentration, e.g., wash conditions of 65°C at a salt concentration of approximately 0.1 x SSC, or the functional equivalent thereof. For example, high stringency conditions may include hybridization at about 42°C in the presence of about 50% formamide; a first wash at about 65°C with about 2 x SSC containing 1% SDS; followed by a second wash at about 65°C with about 0.1 x SSC.

By "substantially pure DNA" is meant DNA that is not part of a milieu in which the DNA naturally occurs, by virtue of separation (partial or total purification) of some or all of the molecules of that milieu, or by virtue of alteration of sequences that flank the claimed DNA. The term therefore includes, for example, a recombinant DNA which is incorporated into a vector, into an autonomously replicating plasmid or virus, or into the genomic DNA of a prokaryote or eukaryote; or which exists as a separate molecule (e.g., a cDNA or a genomic or cDNA fragment produced by polymerase chain reaction

(PCR) or restriction endonuclease digestion) independent of other sequences. It also includes a recombinant DNA which is part of a hybrid gene encoding additional polypeptide sequence, e.g., a fusion protein. Also included is a recombinant DNA which includes a portion
5 of the nucleotides listed in SEQ ID No. 1 or SEQ ID No. 3 or SEQ ID No. 5 which encodes an alternative splice variant of a gene encoding a 28-kDa immunoreactive protein of *Ehrlichia canis*.

The DNA may have at least about 70% sequence identity to the coding sequence of the nucleotides listed in SEQ ID No. 1 or SEQ ID
10 No. 3 or SEQ ID No. 5, preferably at least 75% (e.g. at least 80%); and most preferably at least 90%. The identity between two sequences is a direct function of the number of matching or identical positions. When a subunit position in both of the two sequences is occupied by the same monomeric subunit, e.g., if a given position is occupied by
15 an adenine in each of two DNA molecules, then they are identical at that position. For example, if 7 positions in a sequence 10 nucleotides in length are identical to the corresponding positions in a second 10-nucleotide sequence, then the two sequences have 70% sequence identity. The length of comparison sequences will generally
20 be at least 50 nucleotides, preferably at least 60 nucleotides, more preferably at least 75 nucleotides, and most preferably 100 nucleotides. Sequence identity is typically measured using sequence analysis software (e.g., Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin
25 Biotechnology Center, 1710 University Avenue, Madison, WI 53705).

The present invention comprises a vector comprising a DNA sequence coding for a which encodes a gene encoding a 28-kDa immunoreactive protein of *Ehrlichia canis* and said vector is capable of replication in a host which comprises, in operable linkage: a) an
30 origin of replication; b) a promoter; and c) a DNA sequence coding

for said protein. Preferably, the vector of the present invention contains a portion of the DNA sequence shown in SEQ ID No. 1 or SEQ ID No. 3 or SEQ ID No. 5.

A "vector" may be defined as a replicable nucleic acid construct, e.g., a plasmid or viral nucleic acid. Vectors may be used to amplify and/or express nucleic acid encoding a 28-kDa immunoreactive protein of *Ehrlichia canis*. An expression vector is a replicable construct in which a nucleic acid sequence encoding a polypeptide is operably linked to suitable control sequences capable of effecting expression of the polypeptide in a cell. The need for such control sequences will vary depending upon the cell selected and the transformation method chosen. Generally, control sequences include a transcriptional promoter and/or enhancer, suitable mRNA ribosomal binding sites, and sequences which control the termination of transcription and translation. Methods which are well known to those skilled in the art can be used to construct expression vectors containing appropriate transcriptional and translational control signals. See for example, the techniques described in Sambrook et al., 1989, *Molecular Cloning: A Laboratory Manual* (2nd Ed.), Cold Spring Harbor Press, N.Y. A gene and its transcription control sequences are defined as being "operably linked" if the transcription control sequences effectively control the transcription of the gene. Vectors of the invention include, but are not limited to, plasmid vectors and viral vectors. Preferred viral vectors of the invention are those derived from retroviruses, adenovirus, adeno-associated virus, SV40 virus, or herpes viruses.

By a "substantially pure protein" is meant a protein which has been separated from at least some of those components which naturally accompany it. Typically, the protein is substantially pure when it is at least 60%, by weight, free from the proteins and other

naturally-occurring organic molecules with which it is naturally associated in vivo. Preferably, the purity of the preparation is at least 75%, more preferably at least 90%, and most preferably at least 99%, by weight. A substantially pure 28-kDa immunoreactive protein of *Ehrlichia canis* may be obtained, for example, by extraction from a natural source; by expression of a recombinant nucleic acid encoding a 28-kDa immunoreactive protein of *Ehrlichia canis*; or by chemically synthesizing the protein. Purity can be measured by any appropriate method, e.g., column chromatography such as immunoaffinity chromatography using an antibody specific for a 28-kDa immunoreactive protein of *Ehrlichia canis*, polyacrylamide gel electrophoresis, or HPLC analysis. A protein is substantially free of naturally associated components when it is separated from at least some of those contaminants which accompany it in its natural state. Thus, a protein which is chemically synthesized or produced in a cellular system different from the cell from which it naturally originates will be, by definition, substantially free from its naturally associated components. Accordingly, substantially pure proteins include eukaryotic proteins synthesized in *E. coli*, other prokaryotes, or any other organism in which they do not naturally occur.

In addition to substantially full-length proteins, the invention also includes fragments (e.g., antigenic fragments) of the 28-kDa immunoreactive protein of *Ehrlichia canis* (SEQ ID No. 2 or SEQ ID No. 4 or SEQ ID No. 6). As used herein, "fragment," as applied to a polypeptide, will ordinarily be at least 10 residues, more typically at least 20 residues, and preferably at least 30 (e.g., 50) residues in length, but less than the entire, intact sequence. Fragments of the 28-kDa immunoreactive protein of *Ehrlichia canis* can be generated by methods known to those skilled in the art, e.g., by enzymatic digestion of naturally occurring or recombinant 28-kDa immunoreactive

protein of *Ehrlichia canis*, by recombinant DNA techniques using an expression vector that encodes a defined fragment of 28-kDa immunoreactive protein of *Ehrlichia canis*, or by chemical synthesis. The ability of a candidate fragment to exhibit a characteristic of 28-kDa immunoreactive protein of *Ehrlichia canis* (e.g., binding to an antibody specific for 28-kDa immunoreactive protein of *Ehrlichia canis*) can be assessed by methods described herein. Purified 28-kDa immunoreactive protein of *Ehrlichia canis* or antigenic fragments of 28-kDa immunoreactive protein of *Ehrlichia canis* can be used to generate new antibodies or to test existing antibodies (e.g., as positive controls in a diagnostic assay) by employing standard protocols known to those skilled in the art. Included in this invention are polyclonal antisera generated by using 28-kDa immunoreactive protein of *Ehrlichia canis* or a fragment of 28-kDa immunoreactive protein of *Ehrlichia canis* as the immunogen in, e.g., rabbits. Standard protocols for monoclonal and polyclonal antibody production known to those skilled in this art are employed. The monoclonal antibodies generated by this procedure can be screened for the ability to identify recombinant *Ehrlichia canis* cDNA clones, and to distinguish them from known cDNA clones.

Further included in this invention are fragments of the 28-kDa immunoreactive protein of *Ehrlichia canis* which are encoded at least in part by portions of SEQ ID No. 1 or SEQ ID No. 3 or SEQ ID No. 5, e.g., products of alternative mRNA splicing or alternative protein processing events, or in which a section of the sequence has been deleted. The fragment, or the intact 28-kDa immunoreactive protein of *Ehrlichia canis*, may be covalently linked to another polypeptide, e.g. which acts as a label, a ligand or a means to increase antigenicity.

The phrase "pharmaceutically acceptable" refers to molecular entities and compositions that do not produce an allergic

or similar untoward reaction when administered to a human. The preparation of an aqueous composition that contains a protein as an active ingredient is well understood in the art. Typically, such compositions are prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid prior to injection can also be prepared. The preparation can also be emulsified.

A protein may be formulated into a composition in a neutral or salt form. Pharmaceutically acceptable salts, include the acid addition salts (formed with the free amino groups of the protein) and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like. Salts formed with the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, histidine, procaine and the like.

Upon formulation, solutions will be administered in a manner compatible with the dosage formulation and in such amount as is therapeutically effective. The formulations are easily administered in a variety of dosage forms such as injectable solutions.

For parenteral administration in an aqueous solution, for example, the solution should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose.

These particular aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration. In this connection, sterile aqueous media which can be employed will be known to those of skill in the art in light of the present disclosure. For example, one dosage could be dissolved in 1 mL of isotonic NaCl solution and either added to 1000mL of

hypodermoclysis fluid or injected at the proposed site of infusion, (see for example, "Remington's Pharmaceutical Sciences" 15th Edition, pages 1035-1038 and 1570-1580). Some variation in dosage will necessarily occur depending on the condition of the subject being
5 treated. The person responsible for administration will, in any event, determine the appropriate dose for the individual subject.

As is well known in the art, a given polypeptide may vary in its immunogenicity. It is often necessary therefore to couple the immunogen (e.g., a polypeptide of the present invention) with a
10 carrier. Exemplary and preferred carriers are keyhole limpet hemocyanin (KLH) and human serum albumin. Other carriers may include a variety of lymphokines and adjuvants such as IL2, IL4, IL8 and others.

Means for conjugating a polypeptide to a carrier protein
15 are well known in the art and include glutaraldehyde, m-maleimidobenzoyl-N-hydroxysuccinimide ester, carbo-diimide and bis-biazotized benzidine. It is also understood that the peptide may be conjugated to a protein by genetic engineering techniques that are well known in the art.

20 As is also well known in the art, immunogenicity to a particular immunogen can be enhanced by the use of non-specific stimulators of the immune response known as adjuvants. Exemplary and preferred adjuvants include complete BCG, Detox, (RIBI, Immunochem Research Inc.) ISCOMS and aluminum hydroxide
25 adjuvant (Superphos, Biosector).

As used herein the term "complement" is used to define the strand of nucleic acid which will hybridize to the first nucleic acid sequence to form a double stranded molecule under stringent conditions. Stringent conditions are those that allow hybridization
30 between two nucleic acid sequences with a high degree of homology,

but precludes hybridization of random sequences. For example, hybridization at low temperature and/or high ionic strength is termed low stringency and hybridization at high temperature and/or low ionic strength is termed high stringency. The temperature and ionic strength of a desired stringency are understood to be applicable to particular probe lengths, to the length and base content of the sequences and to the presence of formamide in the hybridization mixture.

As used herein, the term "engineered" or "recombinant" cell is intended to refer to a cell into which a recombinant gene, such as a gene encoding an *Ehrlichia chaffeensis* antigen has been introduced. Therefore, engineered cells are distinguishable from naturally occurring cells which do not contain a recombinantly introduced gene. Engineered cells are thus cells having a gene or genes introduced through the hand of man. Recombinantly introduced genes will either be in the form of a cDNA gene, a copy of a genomic gene, or will include genes positioned adjacent to a promoter not naturally associated with the particular introduced gene. In addition, the recombinant gene may be integrated into the host genome, or it may be contained in a vector, or in a bacterial genome transfected into the host cell.

The following examples are given for the purpose of illustrating various embodiments of the invention and are not meant to limit the present invention in any fashion.

EXAMPLE 1

Ehrlichiae and Purification

Ehrlichia canis (Florida strain and isolates Demon, DJ, Jake, and Fuzzy) were provided by Dr. Edward Breitschwerdt, (College

of Veterinary Medicine, North Carolina State University, Raleigh, NC). *E. canis* (Louisiana strain) was provided by Dr. Richard E. Corstvet (School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA) and *E. canis* (Oklahoma strain) was provided by Dr. Jacqueline Dawson (Centers for Disease Control and Prevention, Atlanta, GA). Propagation of ehrlichiae was performed in DH82 cells with DMEM supplemented with 10% bovine calf serum and 2 mM L-glutamine at 37°C. The intracellular growth in DH82 cells was monitored by presence of *E. canis* morulae using general cytologic staining methods. Cells were harvested when 100% of the cells were infected with ehrlichiae and were then pelleted in a centrifuge at 17,000 x g for 20 min. Cell pellets were disrupted with a Braun-Sonic 2000 sonicator twice at 40W for 30 sec on ice. Ehrlichiae were purified as described previously (Weiss *et al.*, 1975). The lysate was loaded onto discontinuous gradients of 42%-36%-30% renografin, and centrifuged at 80,000 x g for 1 hr. Heavy and light bands containing ehrlichiae were collected and washed with sucrose-phosphate-glutamate buffer (SPG, 218 mM sucrose, 3.8 mM KH₂PO₄, 7.2 mM K₂HPO₄, 4.9 mM glutamate, pH 7.0) and pelleted by centrifugation.

20

EXAMPLE 2

Nucleic Acid Preparation

Ehrlichia canis genomic DNA was prepared by resuspending the renografin-purified ehrlichiae in 600 µl of 10 mM Tris-HCl buffer (pH 7.5) with 1% sodium dodecyl sulfate (SDS, w/v) and 100 ng/ml of proteinase K as described previously (McBride *et al.*, 1996). This mixture was incubated for 1 hr at 56° C, and the nucleic acids were extracted twice with a mixture of phenol/chloroform/isoamyl alcohol (24:24:1). DNA was pelleted by

30

absolute ethanol precipitation, washed once with 70% ethanol, dried and resuspended in 10mM Tris (pH 7.5). Plasmid DNA was purified by using High Pure Plasmid Isolation Kit (Boehringer Mannheim, Indianapolis, IN), and PCR products were purified using a QIAquick PCR
5 Purification Kit (Qiagen, Santa Clarita, CA).

EXAMPLE 3

PCR Amplification of the *E. canis* 28-kDa protein Genes

10 Regions of the *E. canis* *ECa28-1* gene selected for PCR amplification were chosen based on homology observed (>90%) in the consensus sequence generated from Jotun-Hein algorithm alignment of *E. chaffeensis* *p28* and *Cowdria ruminantium* *map-1* genes. Forward primer 793 (5-GCAGGAGCTGTTGGTTACTC-3') (SEQ ID NO. 16) and
15 reverse primer 1330 (5'-CCTTCCTCCAAGTTCTATGCC-3') (SEQ ID NO. 17) corresponded to nucleotides 313-332 and 823-843 of *C. ruminantium* MAP-1 and 307-326 and 834-814 of *E. chaffeensis* P28. *E. canis* (a North Carolina isolate, Jake) DNA was amplified with primers 793 and 1330 with a thermal cycling profile of 95°C for 2
20 min, and 30 cycles of 95°C for 30 sec, 62° C for 1 min, 72°C for 2 min followed by a 72°C extension for 10 min and 4°C hold. PCR products were analyzed on 1% agarose gels. This amplified PCR product was sequenced directly with primers 793 and 1330.

Primers specific for *ECa28SA2* gene designated 46f (5'-
25 ATATACTTCCTACCTAATGTCTCA-3', SEQ ID No. 18) and primer 1330 (SEQ ID No. 17) were used to amplify the targeted region. The amplified product was gel purified and cloned into a TA cloning vector (Invitrogen, Santa Clarita, CA). The clone was sequenced bidirectionally with primers: M13 reverse from the vector, 46f,
30 *ECa28SA2* (5'-AGTGCAGAGTCTTCGGTTTC-3', SEQ ID No. 19), *ECa5.3*

(5'-GTTACTTGCGGAGGACAT-3', SEQ ID No. 20). DNA was amplified with a thermal cycling profile of 95°C for 2 min, and 30 cycles of 95°C for 30 sec, 48°C for 1 min, 72°C for 1 min followed by a 72°C extension for 10 min and 4°C hold.

5

EXAMPLE 4

Sequencing Unknown 5' and 3' Regions of the *ECa28-1* Gene

The full length sequence of *ECa28-1* was determined using
10 a Universal GenomeWalker Kit (CLONTECH, Palo Alto, CA) according to the protocol supplied by the manufacturer. Genomic *E. canis* (Jake isolate) DNA was digested completely with five restriction enzymes (*DraI*, *EcoRV*, *PvuII*, *ScaI*, *StuI*) which produce blunt-ended DNA. An adapter (AP1) supplied in the kit was ligated to each end of *E. canis*
15 DNA. The genomic libraries were used as templates to find the unknown DNA sequence of the *ECa28-1* gene by PCR using a primer complementary to a known portion of the *ECa28-1* sequence and a primer specific for the adapter AP1. Primers specific for *ECa28-1* used for genome walking were designed from the known DNA sequence
20 derived from PCR amplification of *ECa28-1* with primers 793 (SEQ ID NO. 16) and 1330 (SEQ ID NO. 17). Primers 394 (5'-GCATTTCACAGGATCATAGGTAA-3'; nucleotides 687-710, SEQ ID NO. 21) and 394C (5'-TTACCTATGATCCTGT GGAAATGC-3; nucleotides 710-687, SEQ ID NO. 22) were used in conjunction with supplied
25 primer AP1 to amplify the unknown 5' and 3' regions of the *ECa28-1* gene by PCR. A PCR product corresponding to the 5' region of the *ECa28-1* gene amplified with primers 394C and AP1 (2000-bp) was sequenced unidirectionally with primer 793C (5'-GAGTAACCAACAGCTCCTGC-3', SEQ ID No. 23). A PCR product corresponding

to the 3' region of the *ECa28-1* gene amplified with primers 394 and AP1 (580-bp) was sequenced bidirectionally with the same primers. Noncoding regions on the 5' and 3' regions adjacent to the open reading frame were sequenced, and primers EC28OM-F (5'-
5 TCTACTTTGCACTTCC ACTATTGT-3', SEQ ID NO. 24) and EC28OM-R (5'-ATTCTTTTGCCACTATTT TTCTTT-3', SEQ ID NO. 25) complementary to these regions were designed in order to amplify the entire *ECa28-1* gene.

EXAMPLE 5

Sequencing of *E. canis* isolates

DNA was sequenced with an ABI Prism 377 DNA Sequencer (Perkin- Elmer Applied Biosystems, Foster City, CA). The entire *Eca28-1* genes of seven *E. canis* isolates (four from North Carolina, and one each from Oklahoma, Florida, and Louisiana) were amplified by PCR with primers EC28OM-F (SEQ ID No. 24) and EC28OM-R (SEQ ID No. 25) with a thermal cycling profile of 95°C for 5 minutes, and 30 cycles of 95°C for 30 seconds, 62°C for 1 minutes, and 72°C for 2 minutes and a 72°C extension for 10 minutes. The resulting PCR products were bidirectionally sequenced with the same primers.

EXAMPLE 6

Cloning and Expression of *E. canis* *ECa28-1*

The entire *E. canis* *ECa28-1* gene was PCR-amplified with primers-EC28OM-F and EC28OM-R and cloned into pCR2.1-TOPO TA cloning vector to obtain the desired set of restriction enzyme cleavage sites (Invitrogen, Carlsbad, CA). The insert was excised from pCR2.1-

TOPO with *Bst*X I and ligated into pcDNA 3.1 eukaryotic expression vector (Invitrogen, Carlsbad, CA) designated pcDNA3.1/EC28 for subsequent studies. The pcDNA3.1/EC28 plasmid was amplified, and the gene was excised with a *Kpn*I-*Xba*I double digestion and directionally ligated into pThioHis prokaryotic expression vector (Invitrogen, Carlsbad, CA). The clone (designated pThioHis/EC28) produced a recombinant thioredoxin fusion protein in *Escherichia coli* BL21. The recombinant fusion protein was crudely purified in the insoluble phase by centrifugation. The control thioredoxin fusion protein was purified from soluble cell lysates under native conditions using nickel-NTA spin columns (Qiagen, Santa Clarita, CA).

EXAMPLE 7

15

Western Immunoblot Analysis

Recombinant *E. canis* EC28-1 fusion protein was subjected to SDS-polyacrylamide gel electrophoresis (SDS-PAGE) on 4-15% Tris-HCl gradient gels (Bio-Rad, Hercules, CA) and transferred to pure nitrocellulose (Schleicher & Schuell, Keene, NH) using a semi-dry transfer cell (Bio-Rad, Hercules, CA). The membrane was incubated with convalescent phase antisera from an *E. canis*-infected dog diluted 1:5000 for 1 hour, washed, and then incubated with an anti-canine IgG (H & L) alkaline phosphatase-conjugated affinity-purified secondary antibody at 1:1000 for 1 hour (Kirkegaard & Perry Laboratories, Gaithersburg, MD). Bound antibody was visualized with 5-bromo-4-chloro-3-indolyl phosphate/nitroblue tetrazolium (BCIP/NBT) substrate (Kirkegaard & Perry Laboratories, Gaithersburg, MD).

30

EXAMPLE 8

Southern Blot Analysis

To determine if multiple genes homologous to the *ECa28-1* gene were present in the *E. canis* genome, a genomic Southern blot analysis was performed using a standard procedure (Sambrook et al. 1989). *E. canis* genomic DNA digested completely with each of the restriction enzymes *Ban*II, *Eco*RV, *Hae*II, *Kpn*I and *Spe*I, which do not cut within the *ECa28-1* gene, and *Ase*I which digests *ECa28-1* at nucleotides 34, 43 and 656. The probe was produced by PCR amplification with primers EC28OM-F and EC28OM-R and digoxigenin (DIG)-labeled deoxynucleotide triphosphates (dNTPs) (Boehringer Mannheim, Indianapolis, IN) and digested with *Ase*I. The digested probe (566-bp) was separated by agarose gel electrophoresis, gel-purified and then used for hybridization. The completely digested genomic *E. canis* DNA was electrophoresed and transferred to a nylon membrane (Boehringer Mannheim, Indianapolis, IN) and hybridized at 40°C for 16 hr with the *ECa28-1* gene DIG-labeled probe in DIG Easy Hyb buffer according to the manufacturer's protocol (Boehringer Mannheim, Indianapolis, IN). Bound probe was detected with a anti-DIG alkaline phosphatase-conjugated antibody and a luminescent substrate (Boehringer Mannheim, Indianapolis, IN) and exposed to BioMax scientific imaging film (Eastman Kodak, Rochester, NY).

EXAMPLE 9

Sequence Analysis and Comparasion

E. chaffeensis *p28* and *C. ruminantium* *map-1* DNA sequences were obtained from the National Center of Biotechnology Information (NCBI) (World Wide Web site at URL:

http://www.ncbi.nlm.nih.gov/Entrez). Nucleotide and deduced amino acid sequences, and protein and phylogenetic analyses were performed with LASERGENE software (DNASTAR, Inc., Madison, WI). Analysis of post-translational processing was performed by the method of McGeoch and von Heijne for signal sequence recognition using the PSORT program (McGeoch, 1985; von Heijne, 1986) (World Wide Web site at URL: PRIVATE HREF= "http://www.imcb.osaka-u.ac.jp/nakai/form.htm", MACROBUTTON HtmlResAnchor http://www.imcb.osaka-u.ac.jp/nakai/form.htm).

GenBank accession numbers for nucleic acid and amino acid sequences of the *E. canis* *ECa28-1* genes described in this study are: Jake, AF082744; Louisiana, AF082745; Oklahoma, AF082746; Demon, AF082747; DJ, AF082748; Fuzzy, AF082749; Florida, AF082750.

Sequence analysis of *ECa28-1* from seven different strains of *E. canis* was performed with primers designed to amplify the entire gene. Analysis revealed the sequence of this gene was conserved among the isolates from North Carolina (four), Louisiana, Florida and Oklahoma.

EXAMPLE 10

PCR Amplification, Cloning, Sequencing and Expression of *ECa28-1*

Alignment of nucleic acid sequences from *E. chaffeensis* *p28* and *Cowdria ruminantium map-1* using the Jotun-Hein algorithm produced a consensus sequence with regions of high homology (>90%). These homologous regions (nucleotides 313-332 and 823-843 of *C. ruminantium map-1*; 307-326 and 814-834 of *E. chaffeensis p28*) were targeted as primer annealing sites for PCR amplification.

PCR amplification of the *E. canis* *ECa28-1* and *E. chaffeensis p28* gene

was accomplished with primers 793 and 1330, resulting in a 518-bp PCR product. The nucleic acid sequence of the *E. canis* PCR product was obtained by sequencing the product directly with primers 793 and 1330. Analysis of the sequence revealed an open reading frame encoding a protein of 170 amino acids, and alignment of the 518-bp sequence obtained from PCR amplification of *E. canis* with the DNA sequence of *E. chaffeensis* p28 gene revealed a similarity greater than 70%, indicating that the genes were homologous. Adapter PCR with primers 394 and 793C was performed to determine the 5' and 3' segments of the sequence of the entire gene. Primer 394 produced four PCR products (3-kb, 2-kb, 1-kb, and 0.8-kb), and the 0.8-kb product was sequenced bidirectionally using primers 394 and AP1. The deduced sequence overlapped with the 3' end of the 518-bp product, extending the open reading frame 12-bp to a termination codon. An additional 625-bp of non-coding sequence at the 3' end of the *ECa28-1* gene was also sequenced. Primer 394C was used to amplify the 5' end of the *ECa28-1* gene with supplied primer AP1. Amplification with these primers resulted in three PCR products (3.3, 3-kb, and 2-kb). The 2-kb fragment was sequenced unidirectionally with primer 793C. The sequence provided the putative start codon of the *ECa28-1* gene and completed the 834-bp open reading frame encoding a protein of 278 amino acids. An additional 144-bp of readable sequence in the 5' noncoding region of the *ECa28-1* gene was generated. Primers EC28OM-F and EC28OM-R were designed from complementary non-coding regions adjacent to the *ECa28-1* gene.

The PCR product amplified with these primers was sequenced directly with the same primers. The complete DNA sequence (SEQ ID NO. 1) for the *E. canis* *ECa28-1* gene is shown in Figure 1. The *ECa28-1* PCR fragment amplified with these primers contained the entire open reading frame and 17 additional amino

acids from the 5' non-coding primer region. The gene was directionally subcloned into pThioHis expression vector, and *E. coli* (BL21) were transformed with this construct. The expressed ECa28-1-thioredoxin fusion protein was insoluble. The expressed protein had
5 an additional 114 amino acids associated with the thioredoxin, 5 amino acids for the enterokinase recognition site, and 32 amino acids from the multiple cloning site and 5' non-coding primer region at the N-terminus. Convalescent-phase antiserum from an *E. canis* infected dog recognized the expressed recombinant fusion protein, but did not
10 react with the thioredoxin control (Figure 2).

EXAMPLE 11

Sequence Homology

15 The nucleic acid sequence of *ECa28-1* (834-bp) and the *E. chaffeensis* *omp-1* family of genes including signal sequences (*ECa28-1*, *omp-1A*, *B*, *C*, *D*, *E*, and *F*) were aligned using the Clustal method to examine homology between these genes (alignment not shown). Nucleic acid homology was equally conserved (68.9%) between *ECa28-1*, and *E. chaffeensis* *p28* and *omp-1F*. Other putative outer
20 membrane protein genes in the *E. chaffeensis* *omp-1* family, *omp-1D* (68.2%), *omp-1E* (66.7%), *omp-1C* (64.1%), *Cowdria ruminantium* *map-1* (61.8%), *E. canis* 28-kDa protein 1 gene (60%) and 28-kDa protein 2 gene (partial) (59.5%) were also homologous to *ECa28-1*. *E.*
25 *chaffeensis* *omp-1B* had the least nucleic acid homology (45.1%) with *E. Ca28-1*.

Alignment of the predicted amino acid sequences of ECa28-1 (SEQ ID NO. 2) and *E. chaffeensis* P28 revealed amino acid substitutions resulting in four variable regions (VR). Substitutions or
30 deletions in the amino acid sequence and the locations of variable

regions of ECa28-1 and the *E. chaffeensis* OMP-1 family were identified (Figure 3). Amino acid comparison including the signal peptide revealed that ECa28-1 shared the most homology with OMP-1F (68%) of the *E. chaffeensis* OMP-1 family, followed by *E. chaffeensis* P28 (65.5%), OMP-1E (65.1%), OMP-1D (62.9%), OMP-1C (62.9%), *Cowdria ruminantium* MAP-1 (59.4%), *E. canis* 28-kDa protein 1 (55.6%) and 28-kDa protein 2 (partial) (53.6%), and OMP-1B (43.2%). The phylogenetic relationships based on amino acid sequences show that ECa28-1 and *C. ruminantium* MAP-1, *E. chaffeensis* OMP-1 proteins, and *E. canis* 28-kDa proteins 1 and 2 (partial) are related (Figure 4).

EXAMPLE 12

15 Predicted Surface Probability and Immunoreactivity

Analysis of *E. canis* ECa28-1 using hydropathy and hydrophilicity profiles predicted surface-exposed regions on ECa28-1 (Figure 6). Eight major surface-exposed regions consisting of 3 to 9 amino acids were identified on ECa28-1 and were similar to the profile of surface-exposed regions on *E. chaffeensis* P28 (Figure 6). Five of the larger surface-exposed regions on ECa28-1 were located in the N-terminal region of the protein. Surface-exposed hydrophilic regions were found in all four of the variable regions of ECa28-1. Ten T-cell motifs were predicted in the ECa28-1 using the Rothbard-Taylor algorithm (Rothbard and Taylor, 1988), and high antigenicity of the ECa28-1 was predicted by the Jameson-Wolf antigenicity algorithm (Figure 6) (Jameson and Wolf, 1988). Similarities in antigenicity and T-cell motifs were observed between ECa28-1 and *E. chaffeensis* P28.

EXAMPLE 13

Detection of Homologous Genomic Copies of *ECa28-1* Gene

Genomic Southern blot analysis of *E. canis* DNA completely
5 digested independently with restriction enzymes *Ban*II, *Eco*RV, *Hae*II,
*Kpn*I, *Spe*I, which do not have restriction endonuclease sites in the
ECa28-1 gene, and *Ase*I, which has internal restriction endonuclease
sites at nucleotides 34, 43 and 656, revealed the presence of at least
three homologous *ECa28-1* gene copies (Figure 5). Although *ECa28-1*
10 has internal *Ase I* internal restriction sites, the DIG-labeled probe used
in the hybridization experiment targeted a region of the gene within a
single DNA fragment generated by the *Ase*I digestion of the gene.
Digestion with *Ase*I produced 3 bands (approximately 566-bp, 850 -
bp, and 3-kb) that hybridized with the *ECa28-1* DNA probe indicating
15 the presence of multiple genes homologous to *ECa28-1* in the genome.
Digestion with *Eco*RV and *Spe*I produced two bands that hybridized
with the *ECa28-1* gene probe.

EXAMPLE 14

20

Identification of 28-kDa Protein Gene Locus

Specific primers designated *ECaSA3-2* (5'-CTAGGATTA
GGTTATAGTATAAGTT-3', SEQ ID No. 26) corresponding to regions
within *ECa28SA3* and primer 793C (SEQ ID No. 23) which anneals to a
25 region with *ECa28-1* were used to amplify the intergenic region
between gene *SA3* and *ECa28-1*. The 800-bp product was sequenced
with the same primers. DNA was amplified with a thermal cycling
profile of 95°C for 2 min, and 30 cycles of 95°C for 30 sec, 50°C for 1
min, 72°C for 1 min followed by a 72°C extension for 10 min and 4°C
30 hold.

EXAMPLE 15

PCR Amplification of 28-kDa Protein Genes and Identification of the Multiple Gene Locus

5 In order to specifically amplify possible unknown genes downstream of *ECa28SA2*, primer 46f specific for *ECa28SA2*, and primer 1330 which targets a conserved region on the 3' end of *ECa28-1* gene were used for amplification. A 2-kb PCR product was amplified with these primers that contained 2 open reading frames. The first
10 open reading frame contained the known region of gene, *ECaSA2*, and a previously unsequenced 3' portion of the gene. Downstream from *ECaSA2* an additional non identical, but homologous 28-kDa protein gene was found, and designated *ECa28SA3*. The two known loci were joined by amplification with primer SA3-2 specific for the 3' end of
15 *ECa28SA3* gene was used in conjunction with a reverse primer 793C, which anneals at 5' end of *ECa28-1*. An 800-bp PCR product was amplified which contained the 3' end of *Eca28SA3*, the intergenic region between *ECa28SA3* and *ECa28-1* (28NC3) and the 5' end of *Eca28-1*, joining the previously separate loci (Figure 8). The 849-bp
20 open reading frame of *ECa28SA2* encodes a 283 amino acid protein, and *ECa28SA3* has an 840-bp open reading frame encoding a 280 amino acid protein. The intergenic noncoding region between *ECa28SA3* and *ECa28-1* was 345-bp in length (Figures 7 and 8)

25

EXAMPLE 16

Nucleic and Amino Acid Homology

 The nucleic and amino acid sequences of all five *E. canis* 28-kDa protein genes were aligned using the Clustal method to
30 examine the homology between these genes. The nucleic acid

homology ranged from 58 to 75% and a similar amino acid homology of ranging from 67 to 72% was observed between the *E. canis* 28-kDa protein gene members (Figure 9).

5

EXAMPLE 17

Transcriptional Promoter Regions

The intergenic regions between the 28-kDa protein genes were analyzed for promoter sequences by comparison with consensus
10 *Escherichia coli* promoter regions and a promoter from *E. chaffeensis* (Yu *et al.*, 1997; McClure, 1985).

Putative promoter sequences including RBS, -10 and -35 regions were identified in 4 intergenic sequences corresponding to genes *ECa28SA2*, *ECa28SA3*, *ECa28-1*, and *ECa28-2* (Figure 10). The
15 upstream noncoding region of *ECa28SA1* is not known and was not analyzed.

EXAMPLE 18

N-Terminal Signal Sequence

The amino acid sequence analysis revealed that entire *E. canis* *ECa28-1* has a deduced molecular mass of 30.5-kDa and the entire *ECa28SA3* has a deduced molecular mass of 30.7-kDa. Both proteins have a predicted N-terminal signal peptide of 23 amino acids
25 (MNCKKILITTALMSLMYYAPSIS, SEQ ID No. 27), which is similar to that predicted for *E. chaffeensis* P28 (MNYKKILITSALISLISSLPGV SFS, SEQ ID NO. 28), and the OMP-1 protein family (Yu *et al.*, 1998; Ohashi *et al.*, 1998b). A preferred cleavage site for signal peptidases (SIS; Ser-X-Ser) (Oliver, 1985) is found at amino acids 21, 22, and 23 of *ECa28-1*.
30 An additional putative cleavage site at amino acid position 25

(MNCKKILITTALISLMYSIPSISSFS, SEQ ID NO. 29) identical to the predicted cleavage site of *E. chaffeensis* P28 (SFS) was also present, and would result in a mature ECa28-1 with a predicted molecular mass of 27.7-kDa. Signal cleavage site of the previously reported partial
5 sequence of ECa28SA2 is predicted at amino acid 30. However, signal sequence analysis predicted that ECa28SA1 had an uncleavable signal sequence.

Summary

Proteins of similar molecular mass have been identified
10 and cloned from multiple rickettsial agents including *E. canis*, *E. chaffeensis*, and *C. ruminantium* (Reddy *et al.*, 1998; Jongejan *et al.*, 1993; Ohashi *et al.*, 1998). A single locus in *Ehrlichia chaffeensis* with 6 homologous *p28* genes, and 2 loci in *E. canis*, each containing some homologous 28-kDa protein genes have been previously described.

15 The present invention demonstrated the cloning, expression and characterization of genes encoding a mature 28-kDa protein of *E. canis* that are homologous to the *omp-1* multiple gene family of *E. chaffeensis* and the *C. ruminantium map-1* gene. Two new 28-kDa protein genes were identified, *Eca28-1* and *ECa28SA3*.
20 Another *E.canis* 28-kDa protein gene, *ECa28SA2*, partially sequenced previously (Reddy *et al.*, 1998), was sequenced completely in the present invention. Also disclosed is the identification and characterization of a single locus in *E.canis* containing all five *E.canis* 28-kDa protein genes.

25 The *E.canis* 28-kDa protein are homologous to *E.chaffeensis* OMP-1 family and the MAP-1 protein of *C. rumanintium*. The most homologous *E. canis* 28-kDa proteins (*ECa28SA3*, *ECa28-1* and *ECa28-2*) are sequentially arranged in the locus. Homology of these proteins ranged from 67.5% to 72.3%. Divergence among these
30 28-kDa proteins was 27.3% to 38.6%. *E. canis* 28-kDa proteins

ECa28SA1 and ECa28SA2 were the least homologous with homology ranging from 50.9% to 59.4% and divergence of 53.3 to 69.9%. Differences between the genes lies primarily in the four hypervariable regions and suggests that these regions are surface exposed and subject to selective pressure by the immune system. Conservation of *ECa28-1* among seven *E. canis* isolates has been reported (McBride *et al.*, 1999), suggesting that *E. canis* may be clonal in North America. Conversely, significant diversity of *p28* among *E. chaffeensis* isolates has been reported (Yu *et al.*, 1998).

All of the *E. canis* 28-kDa proteins appear to be post translationally processed from a 30-kD protein to a mature 28-kD protein. Recently, a signal sequence was identified on *E. chaffeensis* P28 (Yu *et al.*, 1998), and N-terminal amino acid sequencing has verified that the protein is post-translationally processed resulting in cleavage of the signal sequence to produce a mature protein (Ohashi *et al.*, 1998). The leader sequences of OMP-1F and OMP-1E have also been proposed as leader signal peptides (Ohashi *et al.*, 1998). Signal sequences identified on *E. chaffeensis* OMP-1F, OMP-1E and P28 are homologous to the leader sequence of *E. canis* 28-kDa protein. Promoter sequences for the *p28* genes have not been determined experimentally, but putative promoter regions were identified by comparison with consensus sequences of the RBS, -10 and -35 promoter regions of *E. coli* and other ehrlichiae (Yu *et al.*, 1997; McClure, 1985). Such promoter sequences would allow each gene to potentially be transcribed and translated, suggesting that these genes may be differentially expressed in the host. Persistence of infection in dogs may be related to differential expression of *p28* genes resulting in antigenic changes *in vivo*, thus allowing the organism to evade the immune response.

The *E. canis* 28-kDa protein genes were found to exhibit nucleic acid and amino acid sequence homology with the *E. chaffeensis* *omp-1* gene family and *C. ruminantium* *map-1* gene. Previous studies have identified a 30-kDa protein of *E. canis* that
5 reacts with convalescent phase antisera against *E. chaffeensis*, but was believed to be antigenically distinct (Rikihisa *et al.*, 1994). Findings based on comparison of amino acid substitutions in four variable regions of *E. canis* 28-kDa proteins support this possibility. Together these findings also suggest that the amino acids responsible for the
10 antigenic differences between *E. canis* and *E. chaffeensis* P28 are located in these variable regions and are readily accessible to the immune system. It was reported that immunoreactive peptides were located in the variable regions of the 28-kDa proteins of *C. ruminantium*, *E. chaffeensis* and *E. canis* (Reddy *et al.*, 1998). Analysis
15 of *E. canis* and *E. chaffeensis* P28 revealed that all of the variable regions have predicted surface-exposed amino acids. A study in dogs demonstrated lack of cross protection between *E. canis* and *E. chaffeensis* (Dawson and Ewing, 1992). This observation may be related to antigenic differences in the variable regions of P28 as well
20 as in other immunologically important antigens of these ehrlichial species. Another study found that convalescent phase human antisera from *E. chaffeensis*-infected patients recognized 29/28-kDa protein(s) of *E. chaffeensis* and also reacted with homologous proteins of *E. canis* (Chen *et al.*, 1997). Homologous and crossreactive epitopes on the *E.*
25 *canis* 28-kDa protein and *E. chaffeensis* P28 appear to be recognized by the immune system.

E. canis 28-kDa proteins may be important immunoprotective antigens. Several reports have demonstrated that the 30-kDa antigen of *E. canis* exhibits strong immunoreactivity
30 (Rikihisa *et al.*, 1994; Rikihisa *et al.*, 1992). Antibodies in

convalescent phase antisera from humans and dogs have consistently reacted with proteins in this size range from *E. chaffeensis* and *E. canis*, suggesting that they may be important immunoprotective antigens (Rikihisa *et al.*, 1994; Chen *et al.*, 1994; Chen *et al.*, 1997). In addition, antibodies to 30, 24 and 21-kDa proteins developed early in the immune response to *E. canis* (Rikihisa *et al.*, 1994; Rikihisa *et al.*, 1992), suggesting that these proteins may be especially important in the immune responses in the acute stage of disease. Recently, a family of homologous genes encoding outer membrane proteins with molecular masses of 28-kDa have been identified in *E. chaffeensis*, and mice immunized with recombinant *E. chaffeensis* P28 appeared to have developed immunity against homologous challenge (Ohashi *et al.*, 1998). The P28 of *E. chaffeensis* has been demonstrated to be present in the outer membrane, and immunoelectron microscopy has localized the P28 on the surface on the organism, and thus suggesting that it may serve as an adhesin (Ohashi *et al.*, 1998). It is likely that the 28-kDa proteins of *E. canis* identified in this study have the same location and possibly serve a similar function.

Comparison of *ECa28-1* from different strains of *E. canis* revealed that the gene is apparently completely conserved. Studies involving *E. chaffeensis* have demonstrated immunologic and molecular evidence of diversity in the *ECa28-1*. Patients infected with *E. chaffeensis* have variable immunoreactivity to the 29/28-kDa proteins, suggesting that there is antigenic diversity (Chen *et al.*, 1997). Recently molecular evidence has been generated to support antigenic diversity in the *p28* gene from *E. chaffeensis* (Yu *et al.*, 1998). A comparison of five *E. chaffeensis* isolates revealed that two isolates (Sapulpa and St. Vincent) were 100% identical, but three others (Arkansas, Jax, 91HE17) were divergent by as much as 13.4% at the amino acid level. The conservation of *ECa28-1* suggests that *E*

canis strains found in the United States may be genetically identical, and thus *E. canis* 28-kDa protein is an attractive vaccine candidate for canine ehrlichiosis in the United States. Further analysis of *E. canis* isolates outside the United States may provide information regarding the origin and evolution of *E. canis*. Conservation of the 28-kDa protein makes it an important potential candidate for reliable serodiagnosis of canine ehrlichiosis.

The role of multiple homologous genes is not known at this point; however, persistence of *E. canis* infections in dogs could conceivably be related to antigenic variation due to variable expression of homologous 28-kDa protein genes, thus enabling *E. canis* to evade immune surveillance. Variation of *msp-3* genes in *A. marginale* is partially responsible for variation in the MSP-3 protein, resulting in persistent infections (Alleman *et al.*, 1997). Studies to examine 28-kDa protein gene expression by *E. canis* in acutely and chronically infected dogs would provide insight into the role of the 28-kDa protein gene family in persistence of infection.

The following references were cited herein.

Alleman A.R., et al., (1997) *Infect Immun* **65**: 156-163.

Anderson B.E., et al., (1991) *J Clin Microbiol* **29**: 2838-2842.

Anderson B.E., et al., (1992) *Int J Syst Bacteriol* **42**: 299-302.

Brouqui P., et al., (1992) *J Clin Microbiol* **30**: 1062-1066.

Chen S.M., et al., (1997) *Clin Diag Lab Immunol* **4**: 731-735.

Chen S.M., et al., (1994) *Am J Trop Med Hyg* **50**: 52-58.

Dawson J.E., et al., (1992) *Am J Vet Res* **53**: 1322-1327.

Dawson J.E., et al., (1991) *J Infect Dis* **163**: 564-567.

Donatien, et al., (1935) *Bull Soc Pathol Exot* **28**: 418-9.

Ewing, (1963) *J Am Vet Med Assoc* **143**: 503-6.

Groves M.G., et al., (1975) *Am J Vet Res* **36**: 937-940.

Harrus S., et al., (1998) *J Clin Microbiol* **36**: 73-76.

- Jameson B.A., et al., (1988) *CABIOS* **4**: 181-186.
- Jongejan F., et al., (1993) *Rev Elev Med Vet Pays Trop* **46**: 145-152.
- McBride J.W., et al., (1996) *J Vet Diag Invest* **8**: 441-447.
- McBride, et al., (1999) *Clin Diagn Lab Immunol.*; (In press).
- 5 McClure, (1985) *Ann Rev Biochem* **54**: 171-204.
- McGeoch D.J. (1985) *Virus Res* **3**: 271-286.
- Nyindo M., et al., (1991) *Am J Vet Res* **52**: 1225-1230.
- Nyindo, et al., (1971) *Am J Vet Res* **32**: 1651-58.
- Ohashi, et al., (1998) *Infect Immun* **66**: 132-9.
- 10 Ohashi, et al., (1998) *J Clin Microb* **36**: 2671-80
- Reddy, et al., (1998) *Biochem Biophys Res Comm* **247**: 636-43.
- Rikihisa, et al., (1994) *J Clin Microbiol* **32**: 2107-12.
- Rothbard J.B., et al., (1988) *The EMBO J* **7**: 93-100.
- Sambrook J., et al., (1989) In *Molecular Cloning: A Laboratory*
- 15 *Manual*. Cold Spring Harbor: Cold Spring Harbor Press.
- Troy G.C., et al., (1990) Canine ehrlichiosis. In *Infectious diseases of the dog and cat*. Green C.E. (ed). Philadelphia: W.B. Saunders Co.
- von Heijne, (1986) *Nucl Acids Res* **14**: 4683-90.
- Walker, et al., (1970) *J Am Vet Med Assoc* **157**: 43-55.
- 20 Weiss E., et al., (1975) *Appl Microbiol* **30**: 456-463.
- Yu, et al., (1997) *Gene* **184**: 149-154.
- Yu, et al., (1998) *J. Clin. Microbiol.* (In press).

Any patents or publications mentioned in this specification are indicative of the levels of those skilled in the art to which the invention pertains. These patents and publications are herein
25 incorporated by reference to the same extent as if each individual publication was individually indicated to be incorporated by reference.

One skilled in the art will readily appreciate that the
30 present invention is well adapted to carry out the objects and obtain

the ends and advantages mentioned, as well as those inherent therein. The present examples along with the methods, procedures, treatments, molecules, and specific compounds described herein are presently representative of preferred embodiments, are exemplary, 5 and are not intended as limitations on the scope of the invention. Changes therein and other uses will occur to those skilled in the art which are encompassed within the spirit of the invention as defined by the scope of the claims.

WHAT IS CLAIMED IS:

1. DNA sequences encoding a 30-kilodalton protein of
Ehrlichia canis, wherein said protein is immunoreactive with anti-
5 *Ehrlichia canis* serum.

2. The DNA sequences of claim 1, wherein said protein
has an amino acid sequence selected from the group consisting of SEQ
10 ID No. 2, SEQ ID No. 4 and SEQ ID No. 6.

3. The DNA sequences of claim 2, wherein said protein
has an N-terminal signal sequence.

15

4. The DNA sequences of claim 3, wherein said protein
is post-translationally modified to a 28-kilodalton protein.

20

5. The DNA sequences of claim 1, wherein said DNA has
a sequence selected from the group consisting of SEQ ID No. 1, SEQ ID
No. 3 and SEQ ID No. 5.

25

6. The DNA sequences of claim 1, wherein said DNA is
contained in a single locus of *Ehrlichia canis*.

7. The DNA sequences of claim 6, wherein said locus is a multigene locus of 5.592 kb in length.

5 8. The DNA sequences of claim 7, wherein said locus encoding homologous 28-kilodalton proteins of *Ehrlichia canis*.

9. The DNA sequences of claim 8, wherein said
10 homologous 28-kilodalton proteins of *Ehrlichia canis* are selected from the group consisting of ECa28SA1, ECa28SA2, ECa28SA3, ECa28-1 and ECa28-2.

10. A vector comprising the DNA sequences of claim 1.
15

11. The vector of claim 10, wherein said vector is an expression vector capable of expressing a peptide or polypeptide encoded by the sequence selected from the group consisting of SEQ ID
20 No. 1, SEQ ID No. 3 and SEQ ID No. 5 when said expression vector is introduced into a cell.

12. A recombinant protein comprising the amino acid
25 sequence selected from the group consisting of SEQ ID No. 2, SEQ ID No. 4 and SEQ ID No. 6.

13. The recombinant protein of claim 12, wherein said
30 amino acid sequence is encoded by a nucleic acid segment comprising

a sequence selected from the group consisting of SEQ ID No. 1, SEQ ID No. 3 and SEQ ID No. 5.

5 14. A host cell comprising the nucleic acid segment selected from the group consisting of SEQ ID No. 1, SEQ ID No. 3 and SEQ ID No. 5.

10 15. A method of producing the recombinant protein of claim 12, comprising the steps of:

 obtaining a vector that comprises an expression region comprising a sequence encoding the amino acid sequence selected from the group consisting of SEQ ID No. 2, SEQ ID No. 4 and SEQ ID
15 No. 6 operatively linked to a promoter;

 transfecting said vector into a cell; and

 culturing said cell under conditions effective for expression of said expression region.

20 16. An antibody immunoreactive with an amino acid sequence selected from the group consisting of SEQ ID No. 2, SEQ ID No. 4 and SEQ ID No. 6.

25 17. A method of inhibiting *Ehrlichia canis* infection in a subject comprising the steps of:

 identifying a subject suspected of being exposed to or infected with *Ehrlichia canis*; and

administering a composition comprising a 28-kDa antigen of *Ehrlichia canis* in an amount effective to inhibit an *Ehrlichia canis* infection.

5

18. The method of claim 17, wherein said 28-kDa antigen is a recombinant protein comprising an amino acid sequence selected from the group consisting of SEQ ID No. 2, SEQ ID No. 4 and SEQ ID No. 6.

10

19. The method of claim 18, wherein said recombinant protein is encoded by a gene comprising a sequence selected from the group consisting of SEQ ID No. 1, SEQ ID No. 3 and SEQ ID No. 5.

15

20. The method of claim 18, wherein said recombinant protein is dispersed in a pharmaceutically acceptable carrier.

(SEQ ID NO: 1)

FIG. 1




FIG. 2

MNCKKI LIT TALI SLMYSI PSISFS DII QDGNMG- QN- - - FYISOKYVPSVSHFGSFSAKE- - - - - ESKSTVHV FOLKH 70
 VFTIS SI FL NV Y NPVYGN S- Y- - - M P I E- - - K K T V Y E 70
 KY TITV VL TSFIHF P YSPARASTIH- - - M TA I- - - QSF K V L V DQ 69
 Y VF S IS L GV PA- GSGIN- - - M A V- - - RNT Q 69
 Y FVSS SIL YQ A PVTSDNTI INDSREG V N I RK E APINONTSI KK K 80
 FF ALP SFL G LL BPV DSVS- - - M A V- - - KNP ALY K 70
 B FF TL SFL G L PV D IS- - - M A V- - - RNT ALY IEQ 70
 FF V SFL G PV GD IS- - - V M A- - - KNP ALY Q 70
 FF T V SFL G AV ND V- - - V Q- - - RNT T Q 70
 F ST VSFL GV V EE NPV S- - - V A M TA- - - D RD KA K 71
 DWGSPILKNKHAD- FIVPNYSFRYBNPFLGFA GAI GYSMGGPRIEF EISYEAFDVKSPNINYONDAH- - - RYCALSH- - 145
 N A DA SSQSPD N IR K AS K V I S V M NQGN (SEQ ID NO: 7) 133
 RLSHNI NN DT KSLK Q K K I NS L V H I T N GN L S K GS 145
 N A SNSSPN V S K D L V T NQGN K E- - - K 147
 - - - GDI AQSAN NRTDPALBFQ LIS S S A D L AA QK A N DN DT SODYK FG RED 154
 N VSASSHADAD NNKG K K D L V T NQGN K E- - - DR- - 145
 RCV SRTILS I K L S V V V NQGN K E- - - 146
 E ISSSHNDNH NNKG K K V L N L M T NQGN K- - - Q- - 145
 T S SPENT N K V N N N NQGN K- - - K Y T- - 146
 VKIPSGNINSI BKD K K V N N N RN GG K- - - M- - 145
 HTSAAME- - - ADKFVFLKNEGLIDISLAINACYDI INDKVPVSPYICAGIGTDLISMFEATSPKISYQQKLGISY 217
 HICSDONS GDWYIAKT L L V FML ITB M F T QN LN 133
 - - - NS ADMSSASN L FML VVGEI F V V N L 227
 AI - - - ADK Y V ITFM MV T TAEG FI A V A NV KDFNL F I L 219
 - KA SI - NAT SHY L ML VVSEGI F V IN L 222
 - L LGTETIQD GAGSAS I L K FML V SEGI F I V L 218
 - QDNSG - I PKTS Y L L FML ESI L V L 222
 - NSGGKLSNAG L ML V SEGI F V N L 218
 - DI SSSTAG ITTS MV N T ML ML GM V VIN N L 220
 SINPETS VFI GGHFHRII GNEFRDIPA- - - IVPNSNTTISGPQF- ATVTLNVCHFOLGURFNF (SEQ ID NO: 2) 219
 T SRV A KV KV I - - LL DG NIKVQQS- - - D I S P (SEQ ID NO: 8) 278
 S A KV I TO LAGKGNYP I I D I A (SEQ ID NO: 9) 133
 P T V A V YY GV VITPV LEGAPQITS- - - L IDTGY G V V T (SEQ ID NO: 10) 281
 A A KVA SI - - LKAFATPSSAATPDL S V V (SEQ ID NO: 11) 283
 P S A KV I - - MI E ALAOKONYP I D FY I QL (SEQ ID NO: 12) 280
 A A KV I - - LKAFVTSS- AIPDL I S I (SEQ ID NO: 13) 286
 S A V I - - MI T LTGN- H- TI S V V (SEQ ID NO: 14) 280
 A I K ATSKVFTS GNASSAVSPGF SAI D I I V (SEQ ID NO: 15) 280

FIG. 3




FIG. 4




FIG. 5





FIG. 6

Eca28SA2

ATGAATTGTAAAAAAGTTTTTCACAATAAGTGCATTGATATCATCCATATACTTCCTACCT 60
 M N C K K V F T I S A L I S S I Y F L P

AATGTCTCATACTCTAACCCAGTATATGGTAACAGTATGTATGGTAATTTTTTACATATCA 120
 N V S Y S N P V Y G N S M Y G N F Y I S

GGAAAGTACATGCCAAGTGTTTCCTCATTTTTGGAATTTTTTTCAGCTGAAGAAGAGAAAAAA 180
 G K Y M P S V P H F G I F S A E E E K K

AAGACAACTGTAGTATATGGCTTAAAAGAAAAGTGGGCAGGAGATGCAATATCTAGTCAA 240
 K T T V V Y G L K E N W A G D A I S S Q

AGTCCAGATGATAATTTTTACCATTTCGAAATTACTCATTCAAGTATGCAAGCAACAAATTTT 300
 S P D D N F T I R N Y S F K Y A S N K F

TTAGGGTTTGCAGTAGCTATTGGTTACTCGATAGGCAGTCCAAGAATAGAAGTTGAGATG 360
 L G F A V A I G Y S I G S P R I E V E M

TCTTATGAAGCATTGTGATGTGAAAAATCCAGGTGATAATTACAAAACGGTGCTTACAGG 420
 S Y E A F D V K N P G D N Y K N G A Y R

TATTGTGCTTTATCTCATCAAGATGATGCGGATGATGACATGACTAGTGCAACTGACAAA 480
 Y C A L S H Q D D A D D D M T S A T D K

TTTGTATATTTAATTAATGAAGGATTACTTAACATATCATTTTATGACAAACATATGTTAT 540
 F V Y L I N E G L L N I S F M T N I C Y

GAAACAGCAAGCAAAAATATACCTCTCTCTCCTTACATATGTGCAGGTATTGGTACTGAT 600
 E T A S K N I P L S P Y I C A G I G T D

TTAATTCACATGTTTGAAACTACACATCCTAAAATTTCTTATCAAGGAAAGCTAGGGTTG 660
 L I H M F E T T H P K I S Y Q G K L G L

GCCTACTTCGTAAGTGCAGAGTCTTCGGTTTCTTTTGGTATATATTTTTCATCAAGATTATA 720
 A Y F V S A E S S V S F G I Y F H K I I

AATAATAAGTTTAAAAATGTTCCAGCCATGGTACCTATTAACCTCAGACGAGATAGTAGGA 780
 N N K F K N V P A M V P I N S D E I V G

CCACAGTTTGCAACAGTAACATTAAATGTATGCTACTTTGGATTAGAACTTGGATGTAGG 840
 P Q F A T V T L N V C Y F G L E L G C R

↓ (SEQ ID NO: 3)

TTCAACTTCTAATTTTCGTGGTACACATATCACGAAGCTAAAATTGTTTTTTTATCTCTGC 900
 F N F * (SEQ ID NO: 4)

TGTATACAAGAGAAAAAATAGTAGTGAAAATTACCTAACAATATGACAGTACAAGTTTAC 960
 CAAGCTTATTCTCACAAAACCTTCTGTGTCTTTTATCTCTTTACAATGAAATGTACACTT 1020

FIG. 7-1

AGCTTCACTACTGTAGAGTGTGTTTATCAATGCTTTGTTTATTAATACTCTACATAATAT 1080
GTTAAATTTTTCTTACAAACTCACTAGTAATTTATACTAGAATATATATTCTGACTTGT 1140
ECa28SA3 (SEQ ID NO: 31)

↓
ATTTGCTTTTATACTTCCACTATTGTTAATTTATTTTCACTATTTTAGGTGTAATATGAAT 1200
M N

TGCAAAAAAATTCTTATAACAACGTCATTAATGTCATTAATGTACTATGCTCCAAGCATA 1260
C K K I L I T T A L M S L M Y Y A P S I

TCTTTTTCTGATACTATAACAAGACGATAACACTGGTAGCTTCTACATCAGTGGAAAATAT 1320
S F S D T I Q D D N T G S F Y I S G K Y

GTACCAAGTGTTCACATTTTGGTGTTCCTCAGCTAAAGAAGAAAGAACTCAACTGTT 1380
V P S V S H F G V F S A K E E R N S T V

GGAGTTTTTGGATTAAACATGATTGGAATGGAGGTACAATATCTAACTCTTCTCCAGAA 1440
G V F G L K H D W N G G T I S N S S P E

AATATATTCACAGTTCAAAATTATTCGTTTTAAATACGAAAACAACCCATTCTTAGGGTTT 1500
N I F T V Q N Y S F K Y E N N P F L G F

GCAGGAGCTATTGGTTATTCAATGGGTGGCCCAAGAATAGAAGTTGAAGTTCTGTACGAG 1560
A G A I G Y S M G G P R I E L E V L Y E

ACATTCGATGTGAAAAATCAGAACAATAATTATAAGAACGGCGCACACAGATACTGTGCT 1620
T F D V K N Q N N N Y K N G A H R Y C A

TTATCTCATCATAGTTCAGCAACAAGCATGTCCTCCGCAAGTAACAAATTTGTTTTCTTA 1680
L S H H S S A T S M S S A S N K F V F L

AAAAATGAAGGGTTAATTGACTTATCATTTATGATAAATGCATGCTATGACATAATAATT 1740
K N E G L I D L S F M I N A C Y D I I I

GAAGGAATGCCTTTTTTACCTTATATTTGTGCAGGTGTTGGTACTGATGTTGTTTCCATG 1800
E G M P F S P Y I C A G V G T D V V S M

TTTGAAGCTATAAATCCTAAAATTTCTTACCAAGGAAAACCTAGGATTAGGTTATAGTATA 1860
F E A I N P K I S Y Q G K L G L G Y S I

AGTTCAGAAGCCTCTGTTTTTATCGGTGGACACTTTCACAGAGTCATAGGTAATGAATTT 1920
S E E A S V F I G G H F H R V I G N E F

AGAGACATCCCTGCTATGGTTCCTAGTGGATCAAATCTTCCAGAAAACCAATTTGCAATA 1980
R D I P A M V P S G S N L P E N Q F A I

(SEQ ID NO: 5)
GTAACACTAAATGTGTGTCACTTTGGCATAGAACTTGGAGGAAGATTTAACTTCTGA 2031
V T L N V C H F G I E L G G R F N F *

(SEQ ID NO: 6)

FIG. 7-2




FIG. 8




FIG. 9

```

1  TAACTCTTCTATG-ACATGTTTAAATAGTACTAGTTGCTTCTGTGGTT--TATAAGCGCAGAGAGAA--ATAGT-----TAGTATAAATTAGAAAG-----TTAAA--TATT---AGAAAAGT-CA 28nc1
1  ...TTCGTGG.A--C...A.C.CG...GC..AA.T.G.TT..T.A.CTC.GC.G..T..AAG...A.A..TAG...G--AAAATTACC..AC...TGAC..T.CAAGTTTACC...GCT...CTC.C...C.T.T 28nc2
1  .G..TT.AT.G...CC...A...GA.CTA.AC...T..T.A.TA..GC..C.T..AA..A.A...AA...GGCAAAGNATG...C...GAGG.GGG.GGGGGAC...TT...CTTC--T.TTC.T.T 28nc3
1  ....TT.AT.G...CC...A...CA.CTA.AC...T..T.AWT.A..GC..C.T..AA..A.A...AA...GGCAAAGNATG...C...GAGG.GGG.GGGGGAC...TT...CTTC--T.TGC.T.C 28nc4

112  TATGTTTTTCATTGTCATTGAT-ACACAATA-----AAAGTAGTAT-----TACTTATTAAAT-TTACGTAGTATATTAAATTCCTTACAAAAGCCACTAGTATTTATA 28nc1
136  .G...C...T..CTCT--T.CA..G..A.-GTAC.-CT...CT.CACTACTGTAG.G...GTTATCAATGCTT.GT...-----C.C...A.A..G...TT...CT...A.G... 28nc2
139  A..A..C..T--ACT-----T...A..GCAC..CTC.A.GCTTCCA-GG-A...A.GT-TTCTAATATT..T...CC...CC..TA..A...A...AT.T...A.G... 28nc3
138  C.A...TCYC.CT...T..G...T..AC.ACAG..G...A...CCTCAGG-A...CT.ATCTTCAATATTT..T...CC...C...TA..A...T...AT... 28nc4

222  CTAAAGC-TATACHTTGGCTTGTATTAAATTTGATTTTACTACTGTAAATTTACTT-TCACGTGT---TCTGGGTAAAT
269  .T.G.ATA...T.C.A...GC..A.C.CC...T...T...A...T...TA...
268  .T..TATA...T.C...C...C.C.CC...T...A...TA...
276  .C...ATA...T.C.A...CT...CT...G...G...G...A...AGG-TATAA-+
                                     -35      -10      RBS

```

28nc1 (SEQ ID NO:30)
28nc2 (SEQ ID NO:31)
28nc3 (SEQ ID NO:32)
28nc4 (SEQ ID NO:33)

FIG. 10

SEQUENCE LISTING

<110> Walker, David H.
 McBride, Jere W.
 Yu, Xue-Jie
 <120> Homologous 28-Kilodalton Immunodominant Protein
 Genes of *Ehrlichia canis* and Uses Thereof
 <130> D6152PCT
 <141> 1999-11-30
 <150> 09/261,358
 <151> 1999-03-03
 <160> 33
 <210> 1
 <211> 1607
 <212> DNA
 <213> *Ehrlichia canis*
 <220>
 <223> nucleic acid sequence of *ECa28-1*
 <400> 1

```

attttattta ttaccaatct tatataatat attaaatttc tcttacaaaa 50
atctctaatag ttttataacct aatatatata ttctggcttg tatctacttt 100
gcacttccac tattgttaat ttatttttcac tatttttaggt gtaatatgaa 150
ttgcaaaaaa attccttataa caactgcatt aatatcatta atgtactcta 200
ttccaagcat atctttttct gatactatac aagatggtaa catgggtggt 250
aacttctata ttagtggaag gtaggtacca agtgtctcac attttggtag 300
cttctcagct aaagaagaaa gcaaatcaac tgttggaggt tttggattaa 350
aacatgattg ggatggaagt ccaatactta agaataaaca cgctgacttt 400
actgttccaa actattcggt cagatacgag aacaatccat ttctaggggt 450
tgcaggagct atcgggttact caatgggtgg cccaagaata gaattcgaaa 500
tatcttatga agcattcgac gtaaaaagtc ctaatatcaa ttatcaaaat 550
gacgcgcaca ggtactgcgc tctatctcat cacacatcgg cagccatgga 600
agctgataaa tttgtcttct taaaaaacga agggttaatt gacatatcac 650
ttgcaataaa tgcattgttat gatataataa atgacaaagt acctgtttct 700
ccttatatat gcgcagggtat tggtagtgat ttgatttcta tgtttgaagc 750
tacaagtcct aaaatttcct accaaggaaa actgggcatt agttactcta 800
ttaatccgga aacctctgtt ttcacgggtg ggcatttcca caggatcata 850
ggtaatgagt ttagagatat tcctgcaata gtacctagta actcaactac 900
aataagtgga ccacaatttg caacagtaac actaaatgtg tgtcactttg 950
  
```

```

gtttagaact tggaggaaga ttttaacttct aattttattg ttgccacata 1000
ttaaaaatga tctaaacttg tttttawtat tgctacatac aaaaaaagaa 1050
aaatagtggc aaaagaatgt agcaataaga gggggggggg ggaccaaatt 1100
tatcttctat gcttcccaag ttttttcycg ctatttatga cttaaacaac 1150
agaaggtaat atcctcacgg aaaacttatac ttcaaataatt ttatttatta 1200
ccaatcttat ataatatatt aaatttctct taaaaaatc actagtattt 1250
tataccaaaa tatatatctt gacttgcttt tcttctgcac ttctactatt 1300
tttaatttat ttgtcactat taggttataa taawatgaat tgcmaaagat 1350
ttttcatagc aagtgcattg atatcactaa tgtctttctt acctagcgta 1400
tctttttctg aatcaataca tgaagataat ataaatggta actttttacat 1450
tagtgcaaag tatatgccaa gtgcctcaca ctttggcgta ttttcagtta 1500
aagaagagaa aaacacaaca actggagttt tcggattaaa acaagattgg 1550
gacggagcaa cactaaagga tgcaagcwgc agccacacaw tagaccaag 1600
tacaatg 1607

```

```

<210>      2
<211>     278
<212>      PRT
<213>      Ehrlichia canis
<220>
<223>      amino acid sequence of ECa28-1 protein
<400>      2

```

```

Met Asn Cys Lys Lys Ile Leu Ile Thr Thr Ala Leu Ile Ser Leu
      5                      10                      15
Met Tyr Ser Ile Pro Ser Ile Ser Phe Ser Asp Thr Ile Gln Asp
      20                      25                      30
Gly Asn Met Gly Gly Asn Phe Tyr Ile Ser Gly Lys Tyr Val Pro
      35                      40                      45
Ser Val Ser His Phe Gly Ser Phe Ser Ala Lys Glu Glu Ser Lys
      50                      55                      60
Ser Thr Val Gly Val Phe Gly Leu Lys His Asp Trp Asp Gly Ser
      65                      70                      75
Pro Ile Leu Lys Asn Lys His Ala Asp Phe Thr Val Pro Asn Tyr
      80                      85                      90
Ser Phe Arg Tyr Glu Asn Asn Pro Phe Leu Gly Phe Ala Gly Ala
      95                      100                     105
Ile Gly Tyr Ser Met Gly Gly Pro Arg Ile Glu Phe Glu Ile Ser
      110                     115                     120

```


Tyr Glu Ala Phe Asp Val Lys Ser Pro Asn Ile Asn Tyr Gln Asn
 125 130 135
 Asp Ala His Arg Tyr Cys Ala Leu Ser His His Thr Ser Ala Ala
 140 145 150
 Met Glu Ala Asp Lys Phe Val Phe Leu Lys Asn Glu Gly Leu Ile
 155 160 165
 Asp Ile Ser Leu Ala Ile Asn Ala Cys Tyr Asp Ile Ile Asn Asp
 170 175 180
 Lys Val Pro Val Ser Pro Tyr Ile Cys Ala Gly Ile Gly Thr Asp
 185 190 195
 Leu Ile Ser Met Phe Glu Ala Thr Ser Pro Lys Ile Ser Tyr Gln
 200 205 210
 Gly Lys Leu Gly Ile Ser Tyr Ser Ile Asn Pro Glu Thr Ser Val
 215 220 225
 Phe Ile Gly Gly His Phe His Arg Ile Ile Gly Asn Glu Phe Arg
 230 235 240
 Asp Ile Pro Ala Ile Val Pro Ser Asn Ser Thr Thr Ile Ser Gly
 245 250 255
 Pro Gln Phe Ala Thr Val Thr Leu Asn Val Cys His Phe Gly Leu
 260 265 270
 Glu Leu Gly Gly Arg Phe Asn Phe
 275

<210> 3
 <211> 849
 <212> DNA
 <213> *Ehrlichia canis*
 <220>
 <221> mat_peptide
 <223> nucleic acid sequence of ECa28SA2
 <400> 3

atgaattgta aaaaagtttt cacaataagt gcattgatat catccatata 50
 cttcctacct aatgtctcat actctaacc agtatatggt aacagtatgt 100
 atggtaatttt ttacatatca ggaaagtaca tgccaagtgt tcctcatttt 150
 ggaatttttt cagctgaaga agagaaaaaa aagacaactg tagtatatgg 200
 cttaaaagaa aactgggcag gagatgcaat atctagtcaa agtccagatg 250
 ataattttac cattcgaaat tactcattca agtatgcaag caacaagttt 300

ttaggggtttg cagtagctat tggttactcg ataggcagtc caagaataga 350
 agttgagatg tcttatgaag catttgatgt gaaaaatcca ggtgataatt 400
 acaaaaacgg tgcttacagg tattgtgctt tatctcatca agatgatgcg 450
 gatgatgaca tgactagtgc aactgacaaa tttgtatatt taattaatga 500
 aggattactt aacatatcat ttatgacaaa catatgttat gaaacagcaa 550
 gcaaaaatat acctctctct ccttacatat gtgcagggtat tgggtactgat 600
 ttaattcaca tgtttgaaac tacacatcct aaaatttctt atcaaggaaa 650
 gctaggggttg gcctacttcg taagtgcaga gtcttcgggtt tcttttggtg 700
 tatattttca taaaattata aataataagt ttaaaaatgt tccagccatg 750
 gtacctatta actcagacga gatagtagga ccacagtttg caacagtaac 800
 attaaatgta tgctactttg gattagaact tggatgtagg ttcaacttc 849

<210> 4
 <211> 283
 <212> PRT
 <213> *Ehrlichia canis*
 <220>
 <223> amino acid sequence of ECa28SA2 protein
 <400> 4

| | | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Asn | Cys | Lys | Lys | Val | Phe | Thr | Ile | Ser | Ala | Leu | Ile | Ser | Ser | 5 | 10 | 15 |
| Ile | Tyr | Phe | Leu | Pro | Asn | Val | Ser | Tyr | Ser | Asn | Pro | Val | Tyr | Gly | 20 | 25 | 30 |
| Asn | Ser | Met | Tyr | Gly | Asn | Phe | Tyr | Ile | Ser | Gly | Lys | Tyr | Met | Pro | 35 | 40 | 45 |
| Ser | Val | Pro | His | Phe | Gly | Ile | Phe | Ser | Ala | Glu | Glu | Glu | Lys | Lys | 50 | 55 | 60 |
| Lys | Thr | Thr | Val | Val | Tyr | Gly | Leu | Lys | Glu | Asn | Trp | Ala | Gly | Asp | 65 | 70 | 75 |
| Ala | Ile | Ser | Ser | Gln | Ser | Pro | Asp | Asp | Asn | Phe | Thr | Ile | Arg | Asn | 80 | 85 | 90 |
| Tyr | Ser | Phe | Lys | Tyr | Ala | Ser | Asn | Lys | Phe | Leu | Gly | Phe | Ala | Val | 95 | 100 | 105 |
| Ala | Ile | Gly | Tyr | Ser | Ile | Gly | Ser | Pro | Arg | Ile | Glu | Val | Glu | Met | 110 | 115 | 120 |
| Ser | Tyr | Glu | Ala | Phe | Asp | Val | Lys | Asn | Pro | Gly | Asp | Asn | Tyr | Lys | 125 | 130 | 135 |

| | | |
|---|-----|-----|
| Asn Gly Ala Tyr Arg Tyr Cys Ala Leu Ser His Gln Asp Asp Ala | | |
| | 140 | 150 |
| Asp Asp Asp Met Thr Ser Ala Thr Asp Lys Phe Val Tyr Leu Ile | | |
| | 155 | 165 |
| Asn Glu Gly Leu Leu Asn Ile Ser Phe Met Thr Asn Ile Cys Tyr | | |
| | 170 | 180 |
| Glu Thr Ala Ser Lys Asn Ile Pro Leu Ser Pro Tyr Ile Cys Ala | | |
| | 185 | 195 |
| Gly Ile Gly Thr Asp Leu Ile His Met Phe Glu Thr Thr His Pro | | |
| | 200 | 210 |
| Lys Ile Ser Tyr Gln Gly Lys Leu Gly Leu Ala Tyr Phe Val Ser | | |
| | 215 | 225 |
| Ala Glu Ser Ser Val Ser Phe Gly Ile Tyr Phe His Lys Ile Ile | | |
| | 230 | 240 |
| Asn Asn Lys Phe Lys Asn Val Pro Ala Met Val Pro Ile Asn Ser | | |
| | 245 | 255 |
| Asp Glu Ile Val Gly Pro Gln Phe Ala Thr Val Thr Leu Asn Val | | |
| | 260 | 270 |
| Cys Tyr Phe Gly Leu Glu Leu Gly Cys Arg Phe Asn Phe | | |
| | 275 | 280 |

<210> 5
 <211> 840
 <212> DNA
 <213> *Ehrlichia canis*
 <220>
 <221> mat_peptide
 <223> nucleic acid sequence of ECa28SA3
 <400> 5

```

atgaattgca aaaaaattct tataacaact gcattaatgt cattaatgta 50
ctatgctcca agcatatctt tttctgatac tatacaagac gataacactg 100
gtagcttcta catcagtgga aaatatgtac caagtgtttc acattttggt 150
gttttctcag ctaaagaaga aagaaactca actgttggag tttttggatt 200
aaaacatgat tggaatggag gtacaatatc taactcttct ccagaaaata 250
tattcacagt tcaaaattat tcgttttaaat acgaaaacaa cccattctta 300
gggtttgcag gagctattgg ttattcaatg ggtggcccaa gaatagaact 350
tgaagttctg tacgagacat tcgatgtgaa aaatcagaac aataattata 400
  
```

```

agaacggcgc acacagatac tgtgctttat ctcacatag ttcagcaaca 450
agcatgtcct ccgcaagtaa caaatttggt ttcttaaaaa atgaagggtt 500
aattgactta tcatttatga taaatgcatg ctatgacata ataattgaag 550
gaatgccttt ttcaccttat atttgtgcag gtggttggtac tgatgttggt 600
tccatgtttg aagctataaa tcctaaaatt tcttaccaag gaaaactagg 650
attaggttat agtataagtt cagaagcctc tgtttttatc ggtggacact 700
ttcacagagt cataggtaat gaatttagag acatccctgc tatggttcct 750
agtggatcaa atcttccaga aaaccaatth gcaatagtaa cactaaatgt 800
gtgtcacttt ggcatagaac ttggaggaag atttaacttc 840

```

```

<210>      6
<211>     280
<212>     PRT
<213>     Ehrlichia canis
<220>
<223>     amino acid sequence of ECa28SA3 protein
<400>      6

```

```

Met Asn Cys Lys Lys Ile Leu Ile Thr Thr Ala Leu Met Ser Leu
      5                                10                                15
Met Tyr Tyr Ala Pro Ser Ile Ser Phe Ser Asp Thr Ile Gln Asp
      20                                25                                30
Asp Asn Thr Gly Ser Phe Tyr Ile Ser Gly Lys Tyr Val Pro Ser
      35                                40                                45
Val Ser His Phe Gly Val Phe Ser Ala Lys Glu Glu Arg Asn Ser
      50                                55                                60
Thr Val Gly Val Phe Gly Leu Lys His Asp Trp Asn Gly Gly Thr
      65                                70                                75
Ile Ser Asn Ser Ser Pro Glu Asn Ile Phe Thr Val Gln Asn Tyr
      80                                85                                90
Ser Phe Lys Tyr Glu Asn Asn Pro Phe Leu Gly Phe Ala Gly Ala
      95                                100                               105
Ile Gly Tyr Ser Met Gly Gly Pro Arg Ile Glu Leu Glu Val Leu
      110                               115                               120
Tyr Glu Thr Phe Asp Val Lys Asn Gln Asn Asn Asn Tyr Lys Asn
      125                               130                               135
Gly Ala His Arg Tyr Cys Ala Leu Ser His His Ser Ser Ala Thr
      140                               145                               150

```

| | | |
|-----------------|---|---------|
| Ser Met Ser Ser | Ala Ser Asn Lys Phe Val Phe Leu Lys Asn Glu | |
| | 155 | 160 165 |
| Gly Leu Ile Asp | Leu Ser Phe Met Ile Asn Ala Cys Tyr Asp Ile | |
| | 170 | 175 180 |
| Ile Ile Glu Gly | Met Pro Phe Ser Pro Tyr Ile Cys Ala Gly Val | |
| | 185 | 190 195 |
| Gly Thr Asp Val | Val Ser Met Phe Glu Ala Ile Asn Pro Lys Ile | |
| | 200 | 205 210 |
| Ser Tyr Gln Gly | Lys Leu Gly Leu Gly Tyr Ser Ile Ser Ser Glu | |
| | 215 | 220 225 |
| Ala Ser Val Phe | Ile Gly Gly His Phe His Arg Val Ile Gly Asn | |
| | 230 | 235 240 |
| Glu Phe Arg Asp | Ile Pro Ala Met Val Pro Ser Gly Ser Asn Leu | |
| | 245 | 250 255 |
| Pro Glu Asn Gln | Phe Ala Ile Val Thr Leu Asn Val Cys His Phe | |
| | 260 | 265 270 |
| Gly Ile Glu Leu | Gly Gly Arg Phe Asn Phe | |
| | 275 | 280 |

<210> 7

<211> 133

<212> PRT

<213> *Ehrlichia canis*

<220>

<223> partial amino acid sequence of ECa28SA2 protein

<400> 7

| | | |
|-----------------|---|-------|
| Met Asn Cys Lys | Lys Val Phe Thr Ile Ser Ala Leu Ile Ser Ser | |
| | 5 | 10 15 |
| Ile Tyr Phe Leu | Pro Asn Val Ser Tyr Ser Asn Pro Val Tyr Gly | |
| | 20 | 25 30 |
| Asn Ser Met Tyr | Gly Asn Phe Tyr Ile Ser Gly Lys Tyr Met Pro | |
| | 35 | 40 45 |
| Ser Val Pro His | Phe Gly Ile Phe Ser Ala Glu Glu Glu Lys Lys | |
| | 50 | 55 60 |
| Lys Thr Thr Val | Val Tyr Gly Leu Lys Glu Asn Trp Ala Gly Asp | |
| | 65 | 70 75 |
| Ala Ile Ser Ser | Gln Ser Pro Asp Asp Asn Phe Thr Ile Arg Asn | |
| | 80 | 85 90 |

| | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Tyr | Ser | Phe | Lys | Tyr | Ala | Ser | Asn | Lys | Phe | Leu | Gly | Phe | Ala | Val |
| | | | | 95 | | | | | 100 | | | | | 105 |
| Ala | Ile | Gly | Tyr | Ser | Ile | Gly | Ser | Pro | Arg | Ile | Glu | Val | Glu | Met |
| | | | | 110 | | | | | 115 | | | | | 120 |
| Ser | Tyr | Glu | Ala | Phe | Asp | Val | Lys | Asn | Gln | Gly | Asn | Asn | | |
| | | | | 125 | | | | | 130 | | | | | |

<210> 8

<211> 287

<212> PRT

<213> *Ehrlichia canis*

<220>

<223> amino acid sequence of ECa28SA1 protien

<400> 8

| | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Lys | Tyr | Lys | Lys | Thr | Phe | Thr | Val | Thr | Ala | Leu | Val | Leu | Leu |
| | | | | 5 | | | | | 10 | | | | | 15 |
| Thr | Ser | Phe | Thr | His | Phe | Ile | Pro | Phe | Tyr | Ser | Pro | Ala | Arg | Ala |
| | | | | 20 | | | | | 25 | | | | | 30 |
| Ser | Thr | Ile | His | Asn | Phe | Tyr | Ile | Ser | Gly | Lys | Tyr | Met | Pro | Thr |
| | | | | 35 | | | | | 40 | | | | | 45 |
| Ala | Ser | His | Phe | Gly | Ile | Phe | Ser | Ala | Lys | Glu | Glu | Gln | Ser | Phe |
| | | | | 50 | | | | | 55 | | | | | 60 |
| Thr | Lys | Val | Leu | Val | Gly | Leu | Asp | Gln | Arg | Leu | Ser | His | Asn | Ile |
| | | | | 65 | | | | | 70 | | | | | 75 |
| Ile | Asn | Asn | Asn | Asp | Thr | Ala | Lys | Ser | Leu | Lys | Val | Gln | Asn | Tyr |
| | | | | 80 | | | | | 85 | | | | | 90 |
| Ser | Phe | Lys | Tyr | Lys | Asn | Asn | Pro | Phe | Leu | Gly | Phe | Ala | Gly | Ala |
| | | | | 95 | | | | | 100 | | | | | 105 |
| Ile | Gly | Tyr | Ser | Ile | Gly | Asn | Ser | Arg | Ile | Glu | Leu | Glu | Val | Ser |
| | | | | 110 | | | | | 115 | | | | | 120 |
| His | Glu | Ile | Phe | Asp | Thr | Lys | Asn | Pro | Gly | Asn | Asn | Tyr | Leu | Asn |
| | | | | 125 | | | | | 130 | | | | | 135 |
| Asp | Ser | His | Lys | Tyr | Cys | Ala | Leu | Ser | His | Gly | Ser | His | Ile | Cys |
| | | | | 140 | | | | | 145 | | | | | 150 |
| Ser | Asp | Gly | Asn | Ser | Gly | Asp | Trp | Tyr | Thr | Ala | Lys | Thr | Asp | Lys |
| | | | | 155 | | | | | 160 | | | | | 165 |
| Phe | Val | Leu | Leu | Lys | Asn | Glu | Gly | Leu | Leu | Asp | Val | Ser | Phe | Met |
| | | | | 170 | | | | | 175 | | | | | 180 |

| | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Leu | Asn | Ala | Cys | Tyr | Asp | Ile | Thr | Thr | Glu | Lys | Met | Pro | Phe | Ser |
| | | | | 185 | | | | | 190 | | | | | 195 |
| Pro | Tyr | Ile | Cys | Ala | Gly | Ile | Gly | Thr | Asp | Leu | Ile | Ser | Met | Phe |
| | | | | 200 | | | | | 205 | | | | | 210 |
| Glu | Thr | Thr | Gln | Asn | Lys | Ile | Ser | Tyr | Gln | Gly | Lys | Leu | Gly | Leu |
| | | | | 215 | | | | | 220 | | | | | 225 |
| Asn | Tyr | Thr | Ile | Asn | Ser | Arg | Val | Ser | Val | Phe | Ala | Gly | Gly | His |
| | | | | 230 | | | | | 235 | | | | | 240 |
| Phe | His | Lys | Val | Ile | Gly | Asn | Glu | Phe | Lys | Gly | Ile | Pro | Thr | Leu |
| | | | | 245 | | | | | 250 | | | | | 255 |
| Leu | Pro | Asp | Gly | Ser | Asn | Ile | Lys | Val | Gln | Gln | Ser | Ala | Thr | Val |
| | | | | 260 | | | | | 265 | | | | | 270 |
| Thr | Leu | Asp | Val | Cys | His | Phe | Gly | Leu | Glu | Ile | Gly | Ser | Arg | Phe |
| | | | | 275 | | | | | 280 | | | | | 285 |
| Phe | Phe | | | | | | | | | | | | | |

<210> 9
 <211> 281
 <212> PRT
 <213> *Ehrlichia chaffeensis*
 <220>
 <223> amino acid sequence of *E. chaffeensis* P28
 <400> 9

| | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Asn | Tyr | Lys | Lys | Val | Phe | Ile | Thr | Ser | Ala | Leu | Ile | Ser | Leu |
| | | | | 5 | | | | | 10 | | | | | 15 |
| Ile | Ser | Ser | Leu | Pro | Gly | Val | Ser | Phe | Ser | Asp | Pro | Ala | Gly | Ser |
| | | | | 20 | | | | | 25 | | | | | 30 |
| Gly | Ile | Asn | Gly | Asn | Phe | Tyr | Ile | Ser | Gly | Lys | Tyr | Met | Pro | Ser |
| | | | | 35 | | | | | 40 | | | | | 45 |
| Ala | Ser | His | Phe | Gly | Val | Phe | Ser | Ala | Lys | Glu | Glu | Arg | Asn | Thr |
| | | | | 50 | | | | | 55 | | | | | 60 |
| Thr | Val | Gly | Val | Phe | Gly | Leu | Lys | Gln | Asn | Trp | Asp | Gly | Ser | Ala |
| | | | | 65 | | | | | 70 | | | | | 75 |
| Ile | Ser | Asn | Ser | Ser | Pro | Asn | Asp | Val | Phe | Thr | Val | Ser | Asn | Tyr |
| | | | | 80 | | | | | 85 | | | | | 90 |
| Ser | Phe | Lys | Tyr | Glu | Asn | Asn | Pro | Phe | Leu | Gly | Phe | Ala | Gly | Ala |
| | | | | 95 | | | | | 100 | | | | | 105 |

| | |
|---|-------------------------|
| Ile Gly Tyr Ser Met Asp Gly Pro Arg | Ile Glu Leu Glu Val Ser |
| 110 | 115 120 |
| Tyr Glu Thr Phe Asp Val Lys Asn Gln Gly Asn Asn Tyr Lys Asn | |
| 125 | 130 135 |
| Glu Ala His Arg Tyr Cys Ala Leu Ser His Asn Ser Ala Ala Asp | |
| 140 | 145 150 |
| Met Ser Ser Ala Ser Asn Asn Phe Val Phe Leu Lys Asn Glu Gly | |
| 155 | 160 165 |
| Leu Leu Asp Ile Ser Phe Met Leu Asn Ala Cys Tyr Asp Val Val | |
| 170 | 175 180 |
| Gly Glu Gly Ile Pro Phe Ser Pro Tyr Ile Cys Ala Gly Ile Gly | |
| 185 | 190 195 |
| Thr Asp Leu Val Ser Met Phe Glu Ala Thr Asn Pro Lys Ile Ser | |
| 200 | 205 210 |
| Tyr Gln Gly Lys Leu Gly Leu Ser Tyr Ser Ile Ser Pro Glu Ala | |
| 215 | 220 225 |
| Ser Val Phe Ile Gly Gly His Phe His Lys Val Ile Gly Asn Glu | |
| 230 | 235 240 |
| Phe Arg Asp Ile Pro Thr Ile Ile Pro Thr Gly Ser Thr Leu Ala | |
| 245 | 250 255 |
| Gly Lys Gly Asn Tyr Pro Ala Ile Val Ile Leu Asp Val Cys His | |
| 260 | 265 270 |
| Phe Gly Ile Glu Leu Gly Gly Arg Phe Ala Phe | |
| 275 | 280 |

<210> 10

<211> 283

<212> PRT

<213> *Ehrlichia chaffeensis*

<220>

<223> amino acid sequence of *E. chaffeensis* OMP-1B

<400> 10

| |
|---|
| Met Asn Tyr Lys Lys Ile Phe Val Ser Ser Ala Leu Ile Ser Leu |
| 5 10 15 |
| Met Ser Ile Leu Pro Tyr Gln Ser Phe Ala Asp Pro Val Thr Ser |
| 20 25 30 |

| | | |
|-----------------|---------------------|-------------------------|
| Asn Asp Thr Gly | Ile Asn Asp Ser Arg | Glu Gly Phe Tyr Ile Ser |
| 35 | 40 | 45 |
| Val Lys Tyr Asn | Pro Ser Ile Ser His | Phe Arg Lys Phe Ser Ala |
| 50 | 55 | 60 |
| Glu Glu Ala Pro | Ile Asn Gly Asn Thr | Ser Ile Thr Lys Lys Val |
| 65 | 70 | 75 |
| Phe Gly Leu Lys | Lys Asp Gly Asp Ile | Ala Gln Ser Ala Asn Phe |
| 80 | 85 | 90 |
| Asn Arg Thr Asp | Pro Ala Leu Glu Phe | Gln Asn Asn Leu Ile Ser |
| 95 | 100 | 105 |
| Gly Phe Ser Gly | Ser Ile Gly Tyr Ala | Met Asp Gly Pro Arg Ile |
| 110 | 115 | 120 |
| Glu Leu Glu Ala | Ala Tyr Gln Lys Phe | Asp Ala Lys Asn Pro Asp |
| 125 | 130 | 135 |
| Asn Asn Asp Thr | Asn Ser Gly Asp Tyr | Tyr Lys Tyr Phe Gly Leu |
| 140 | 145 | 150 |
| Ser Arg Glu Asp | Ala Ile Ala Asp Lys | Lys Tyr Val Val Leu Lys |
| 155 | 160 | 165 |
| Asn Glu Gly Ile | Thr Phe Met Ser Leu | Met Val Asn Thr Cys Tyr |
| 170 | 175 | 180 |
| Asp Ile Thr Ala | Glu Gly Val Pro Phe | Ile Pro Tyr Ala Cys Ala |
| 185 | 190 | 195 |
| Gly Val Gly Ala | Asp Leu Ile Asn Val | Phe Lys Asp Phe Asn Leu |
| 200 | 205 | 210 |
| Lys Phe Ser Tyr | Gln Gly Lys Ile Gly | Ile Ser Tyr Pro Ile Thr |
| 215 | 220 | 225 |
| Pro Glu Val Ser | Ala Phe Ile Gly Gly | Tyr Tyr His Gly Val Ile |
| 230 | 235 | 240 |
| Gly Asn Asn Phe | Asn Lys Ile Pro Val | Ile Thr Pro Val Val Leu |
| 245 | 250 | 255 |
| Glu Gly Ala Pro | Gln Thr Thr Ser Ala | Leu Val Thr Ile Asp Thr |
| 260 | 265 | 270 |
| Gly Tyr Phe Gly | Gly Glu Val Gly Val | Arg Phe Thr Phe |
| 275 | 280 | |

<210> 11

<211> 280

<212> PRT
 <213> *Ehrlichia chaffeensis*
 <220>
 <223> amino acid sequence of *E. chaffeensis* OMP-1C
 <400> 11

| | | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Asn | Cys | Lys | Lys | Phe | Phe | Ile | Thr | Thr | Ala | Leu | Ala | Leu | Pro | 5 | 10 | 15 |
| Met | Ser | Phe | Leu | Pro | Gly | Ile | Leu | Leu | Ser | Glu | Pro | Val | Gln | Asp | 20 | 25 | 30 |
| Asp | Ser | Val | Ser | Gly | Asn | Phe | Tyr | Ile | Ser | Gly | Lys | Tyr | Met | Pro | 35 | 40 | 45 |
| Ser | Ala | Ser | His | Phe | Gly | Val | Phe | Ser | Ala | Lys | Glu | Glu | Lys | Asn | 50 | 55 | 60 |
| Pro | Thr | Val | Ala | Leu | Tyr | Gly | Leu | Lys | Gln | Asp | Trp | Asn | Gly | Val | 65 | 70 | 75 |
| Ser | Ala | Ser | Ser | His | Ala | Asp | Ala | Asp | Phe | Asn | Asn | Lys | Gly | Tyr | 80 | 85 | 90 |
| Ser | Phe | Lys | Tyr | Glu | Asn | Asn | Pro | Phe | Leu | Gly | Phe | Ala | Gly | Ala | 95 | 100 | 105 |
| Ile | Gly | Tyr | Ser | Met | Gly | Gly | Pro | Arg | Ile | Glu | Phe | Glu | Val | Ser | 110 | 115 | 120 |
| Tyr | Glu | Thr | Phe | Asp | Val | Lys | Asn | Gln | Gly | Gly | Asn | Tyr | Lys | Asn | 125 | 130 | 135 |
| Asp | Ala | His | Arg | Tyr | Cys | Ala | Leu | Asp | Arg | Lys | Ala | Ser | Ser | Thr | 140 | 145 | 150 |
| Asn | Ala | Thr | Ala | Ser | His | Tyr | Val | Leu | Leu | Lys | Asn | Glu | Gly | Leu | 155 | 160 | 165 |
| Leu | Asp | Ile | Ser | Leu | Met | Leu | Asn | Ala | Cys | Tyr | Asp | Val | Val | Ser | 170 | 175 | 180 |
| Glu | Gly | Ile | Pro | Phe | Ser | Pro | Tyr | Ile | Cys | Ala | Gly | Val | Gly | Thr | 185 | 190 | 195 |
| Asp | Leu | Ile | Ser | Met | Phe | Glu | Ala | Ile | Asn | Pro | Lys | Ile | Ser | Tyr | 200 | 205 | 210 |
| Gln | Gly | Lys | Leu | Gly | Leu | Ser | Tyr | Ser | Ile | Asn | Pro | Glu | Ala | Ser | 215 | 220 | 225 |
| Val | Phe | Val | Gly | Gly | His | Phe | His | Lys | Val | Ala | Gly | Asn | Glu | Phe | 230 | 235 | 240 |

| | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Arg | Asp | Ile | Ser | Thr | Leu | Lys | Ala | Phe | Ala | Thr | Pro | Ser | Ser | Ala |
| | | | | | 245 | | | | 250 | | | | | 255 |
| Ala | Thr | Pro | Asp | Leu | Ala | Thr | Val | Thr | Leu | Ser | Val | Cys | His | Phe |
| | | | | | 260 | | | | 265 | | | | | 270 |
| Gly | Val | Glu | Leu | Gly | Gly | Arg | Phe | Asn | Phe | | | | | |
| | | | | | 275 | | | | 280 | | | | | |

<210> 12
 <211> 286
 <212> PRT
 <213> *Ehrlichia chaffeensis*
 <220>
 <223> amino acid sequence of *E. chaffeensis* OMP-1D
 <400> 12

| | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Asn | Cys | Glu | Lys | Phe | Phe | Ile | Thr | Thr | Ala | Leu | Thr | Leu | Leu |
| | | | | 5 | | | | | 10 | | | | | 15 |
| Met | Ser | Phe | Leu | Pro | Gly | Ile | Ser | Leu | Ser | Asp | Pro | Val | Gln | Asp |
| | | | | 20 | | | | | 25 | | | | | 30 |
| Asp | Asn | Ile | Ser | Gly | Asn | Phe | Tyr | Ile | Ser | Gly | Lys | Tyr | Met | Pro |
| | | | | 35 | | | | | 40 | | | | | 45 |
| Ser | Ala | Ser | His | Phe | Gly | Val | Phe | Ser | Ala | Lys | Glu | Glu | Arg | Asn |
| | | | | 50 | | | | | 55 | | | | | 60 |
| Thr | Thr | Val | Gly | Val | Phe | Gly | Ile | Glu | Gln | Asp | Trp | Asp | Arg | Cys |
| | | | | 65 | | | | | 70 | | | | | 75 |
| Val | Ile | Ser | Arg | Thr | Thr | Leu | Ser | Asp | Ile | Phe | Thr | Val | Pro | Asn |
| | | | | 80 | | | | | 85 | | | | | 90 |
| Tyr | Ser | Phe | Lys | Tyr | Glu | Asn | Asn | Leu | Phe | Ser | Gly | Phe | Ala | Gly |
| | | | | 95 | | | | | 100 | | | | | 105 |
| Ala | Ile | Gly | Tyr | Ser | Met | Asp | Gly | Pro | Arg | Ile | Glu | Leu | Glu | Val |
| | | | | 110 | | | | | 115 | | | | | 120 |
| Ser | Tyr | Glu | Ala | Phe | Asp | Val | Lys | Asn | Gln | Gly | Asn | Asn | Tyr | Lys |
| | | | | 125 | | | | | 130 | | | | | 135 |
| Asn | Glu | Ala | His | Arg | Tyr | Tyr | Ala | Leu | Ser | His | Leu | Leu | Gly | Thr |
| | | | | 140 | | | | | 145 | | | | | 150 |
| Glu | Thr | Gln | Ile | Asp | Gly | Ala | Gly | Ser | Ala | Ser | Val | Phe | Leu | Ile |
| | | | | 155 | | | | | 160 | | | | | 165 |

| | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Asn | Glu | Gly | Leu | Leu | Asp | Lys | Ser | Phe | Met | Leu | Asn | Ala | Cys | Tyr |
| | | | | 170 | | | | | 175 | | | | | 180 |
| Asp | Val | Ile | Ser | Glu | Gly | Ile | Pro | Phe | Ser | Pro | Tyr | Ile | Cys | Ala |
| | | | | 185 | | | | | 190 | | | | | 195 |
| Gly | Ile | Gly | Ile | Asp | Leu | Val | Ser | Met | Phe | Glu | Ala | Ile | Asn | Pro |
| | | | | 200 | | | | | 205 | | | | | 210 |
| Lys | Ile | Ser | Tyr | Gln | Gly | Lys | Leu | Gly | Leu | Ser | Tyr | Pro | Ile | Ser |
| | | | | 215 | | | | | 220 | | | | | 225 |
| Pro | Glu | Ala | Ser | Val | Phe | Ile | Gly | Gly | His | Phe | His | Lys | Val | Ile |
| | | | | 230 | | | | | 235 | | | | | 240 |
| Gly | Asn | Glu | Phe | Arg | Asp | Ile | Pro | Thr | Met | Ile | Pro | Ser | Glu | Ser |
| | | | | 245 | | | | | 250 | | | | | 255 |
| Ala | Leu | Ala | Gly | Lys | Gly | Asn | Tyr | Pro | Ala | Ile | Val | Thr | Leu | Asp |
| | | | | 260 | | | | | 265 | | | | | 270 |
| Val | Phe | Tyr | Phe | Gly | Ile | Glu | Leu | Gly | Gly | Arg | Phe | Asn | Phe | Gln |
| | | | | 275 | | | | | 280 | | | | | 285 |

Leu

<210> 13
 <211> 278
 <212> PRT
 <213> *Ehrlichia chaffeensis*
 <220>
 <223> amino acid sequence of *E. chaffeensis* OMP-1E
 <400> 13

| | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Asn | Cys | Lys | Lys | Phe | Phe | Ile | Thr | Thr | Ala | Leu | Val | Ser | Leu |
| | | | | 5 | | | | | 10 | | | | | 15 |
| Met | Ser | Phe | Leu | Pro | Gly | Ile | Ser | Phe | Ser | Asp | Pro | Val | Gln | Gly |
| | | | | 20 | | | | | 25 | | | | | 30 |
| Asp | Asn | Ile | Ser | Gly | Asn | Phe | Tyr | Val | Ser | Gly | Lys | Tyr | Met | Pro |
| | | | | 35 | | | | | 40 | | | | | 45 |
| Ser | Ala | Ser | His | Phe | Gly | Met | Phe | Ser | Ala | Lys | Glu | Glu | Lys | Asn |
| | | | | 50 | | | | | 55 | | | | | 60 |
| Pro | Thr | Val | Ala | Leu | Tyr | Gly | Leu | Lys | Gln | Asp | Trp | Glu | Gly | Ile |
| | | | | 65 | | | | | 70 | | | | | 75 |
| Ser | Ser | Ser | Ser | His | Asn | Asp | Asn | His | Phe | Asn | Asn | Lys | Gly | Tyr |
| | | | | 80 | | | | | 85 | | | | | 90 |

Ser Phe Lys Tyr Glu Asn Asn Pro Phe Leu Gly Phe Ala Gly Ala
 95 100 105
 Ile Gly Tyr Ser Met Gly Gly Pro Arg Val Glu Phe Glu Val Ser
 110 115 120
 Tyr Glu Thr Phe Asp Val Lys Asn Gln Gly Asn Asn Tyr Lys Asn
 125 130 135
 Asp Ala His Arg Tyr Cys Ala Leu Gly Gln Gln Asp Asn Ser Gly
 140 145 150
 Ile Pro Lys Thr Ser Lys Tyr Val Leu Leu Lys Ser Glu Gly Leu
 155 160 165
 Leu Asp Ile Ser Phe Met Leu Asn Ala Cys Tyr Asp Ile Ile Asn
 170 175 180
 Glu Ser Ile Pro Leu Ser Pro Tyr Ile Cys Ala Gly Val Gly Thr
 185 190 195
 Asp Leu Ile Ser Met Phe Glu Ala Thr Asn Pro Lys Ile Ser Tyr
 200 205 210
 Gln Gly Lys Leu Gly Leu Ser Tyr Ser Ile Asn Pro Glu Ala Ser
 215 220 225
 Val Phe Ile Gly Gly His Phe His Lys Val Ile Gly Asn Glu Phe
 230 235 240
 Arg Asp Ile Pro Thr Leu Lys Ala Phe Val Thr Ser Ser Ala Thr
 245 250 255
 Pro Asp Leu Ala Ile Val Thr Leu Ser Val Cys His Phe Gly Ile
 260 265 270
 Glu Leu Gly Gly Arg Phe Asn Phe
 275

<210> 14
 <211> 280
 <212> PRT
 <213> *Ehrlichia chaffeensis*
 <220>
 <223> amino acid sequence of *E. chaffeensis* OMP-1F
 <400> 14

Met Asn Cys Lys Lys Phe Phe Ile Thr Thr Thr Leu Val Ser Leu
 5 10 15

| | | |
|---|-----|---------|
| Met Ser Phe Leu Pro Gly Ile Ser Phe Ser Asp Ala Val Gln Asn | | |
| | 20 | 25 30 |
| Asp Asn Val Gly Gly Asn Phe Tyr Ile Ser Gly Lys Tyr Val Pro | | |
| | 35 | 40 45 |
| Ser Val Ser His Phe Gly Val Phe Ser Ala Lys Gln Glu Arg Asn | | |
| | 50 | 55 60 |
| Thr Thr Thr Gly Val Phe Gly Leu Lys Gln Asp Trp Asp Gly Ser | | |
| | 65 | 70 75 |
| Thr Ile Ser Lys Asn Ser Pro Glu Asn Thr Phe Asn Val Pro Asn | | |
| | 80 | 85 90 |
| Tyr Ser Phe Lys Tyr Glu Asn Asn Pro Phe Leu Gly Phe Ala Gly | | |
| | 95 | 100 105 |
| Ala Val Gly Tyr Leu Met Asn Gly Pro Arg Ile Glu Leu Glu Met | | |
| | 110 | 115 120 |
| Ser Tyr Glu Thr Phe Asp Val Lys Asn Gln Gly Asn Asn Tyr Lys | | |
| | 125 | 130 135 |
| Asn Asp Ala His Lys Tyr Tyr Ala Leu Thr His Asn Ser Gly Gly | | |
| | 140 | 145 150 |
| Lys Leu Ser Asn Ala Gly Asp Lys Phe Val Phe Leu Lys Asn Glu | | |
| | 155 | 160 165 |
| Gly Leu Leu Asp Ile Ser Leu Met Leu Asn Ala Cys Tyr Asp Val | | |
| | 170 | 175 180 |
| Ile Ser Glu Gly Ile Pro Phe Ser Pro Tyr Ile Cys Ala Gly Val | | |
| | 185 | 190 195 |
| Gly Thr Asp Leu Ile Ser Met Phe Glu Ala Ile Asn Pro Lys Ile | | |
| | 200 | 205 210 |
| Ser Tyr Gln Gly Lys Leu Gly Leu Ser Tyr Ser Ile Ser Pro Glu | | |
| | 215 | 220 225 |
| Ala Ser Val Phe Val Gly Gly His Phe His Lys Val Ile Gly Asn | | |
| | 230 | 235 240 |
| Glu Phe Arg Asp Ile Pro Ala Met Ile Pro Ser Thr Ser Thr Leu | | |
| | 245 | 250 255 |
| Thr Gly Asn His Phe Thr Ile Val Thr Leu Ser Val Cys His Phe | | |
| | 260 | 265 270 |
| Gly Val Glu Leu Gly Gly Arg Phe Asn Phe | | |
| | 275 | 280 |

<210> 15
 <211> 284
 <212> PRT
 <213> *Cowdria ruminantium*
 <220>
 <223> amino acid sequence of *C. ruminantium* MAP-1
 <400> 15

| | | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Asn | Cys | Lys | Lys | Ile | Phe | Ile | Thr | Ser | Thr | Leu | Ile | Ser | Leu | 5 | 10 | 15 |
| Val | Ser | Phe | Leu | Pro | Gly | Val | Ser | Phe | Ser | Asp | Val | Ile | Gln | Glu | 20 | 25 | 30 |
| Glu | Asn | Asn | Pro | Val | Gly | Ser | Val | Tyr | Ile | Ser | Ala | Lys | Tyr | Met | 35 | 40 | 45 |
| Pro | Thr | Ala | Ser | His | Phe | Gly | Lys | Met | Ser | Ile | Lys | Glu | Asp | Ser | 50 | 55 | 60 |
| Arg | Asp | Thr | Lys | Ala | Val | Phe | Gly | Leu | Lys | Lys | Asp | Trp | Asp | Gly | 65 | 70 | 75 |
| Val | Lys | Thr | Pro | Ser | Gly | Asn | Thr | Asn | Ser | Ile | Phe | Thr | Glu | Lys | 80 | 85 | 90 |
| Asp | Tyr | Ser | Phe | Lys | Tyr | Glu | Asn | Asn | Pro | Phe | Leu | Gly | Phe | Ala | 95 | 100 | 105 |
| Gly | Ala | Val | Gly | Tyr | Ser | Met | Asn | Gly | Pro | Arg | Ile | Glu | Phe | Glu | 110 | 115 | 120 |
| Val | Ser | Tyr | Glu | Thr | Phe | Asp | Val | Arg | Asn | Pro | Gly | Gly | Asn | Tyr | 125 | 130 | 135 |
| Lys | Asn | Asp | Ala | His | Met | Tyr | Cys | Ala | Leu | Asp | Thr | Ala | Ser | Ser | 140 | 145 | 150 |
| Ser | Thr | Ala | Gly | Ala | Thr | Thr | Ser | Val | Met | Val | Lys | Asn | Glu | Asn | 155 | 160 | 165 |
| Leu | Thr | Asp | Ile | Ser | Leu | Met | Leu | Asn | Ala | Cys | Tyr | Asp | Ile | Met | 170 | 175 | 180 |
| Leu | Asp | Gly | Met | Pro | Val | Ser | Pro | Tyr | Val | Cys | Ala | Gly | Ile | Gly | 185 | 190 | 195 |
| Thr | Asp | Leu | Val | Ser | Val | Ile | Asn | Ala | Thr | Asn | Pro | Lys | Leu | Ser | 200 | 205 | 210 |
| Tyr | Gln | Gly | Lys | Leu | Gly | Ile | Ser | Tyr | Ser | Ile | Asn | Pro | Glu | Ala | 215 | 220 | 225 |

| | | |
|---|-----|---------|
| Ser Ile Phe Ile Gly Gly His Phe His Arg Val Ile Gly Asn Glu | | |
| | 230 | 235 240 |
| Phe Lys Asp Ile Ala Thr Ser Lys Val Phe Thr Ser Ser Gly Asn | | |
| | 245 | 250 255 |
| Ala Ser Ser Ala Val Ser Pro Gly Phe Ala Ser Ala Ile Leu Asp | | |
| | 260 | 265 270 |
| Val Cys His Phe Gly Ile Glu Ile Gly Gly Arg Phe Val Phe | | |
| | 275 | 280 |

<210> 16
 <211> 20
 <212> DNA
 <213> artificial sequence
 <220>
 <221> primer_bind
 <222> nucleotides 313-332 of *C. ruminantium* MAP-1,
 also nucleotides 307-326 of *E. chaffeensis* P28
 <223> forward primer 793 for PCR
 <400> 16

gcaggagctg ttggttactc 20

<210> 17
 <211> 21
 <212> DNA
 <213> artificial sequence
 <220>
 <221> primer_bind
 <222> nucleotides 823-843 of *C. ruminantium* MAP-1,
 also nucleotides 814-834 of *E. chaffeensis* P28
 <223> reverse primer 1330 for PCR
 <400> 17

ccttcctcca agttctatgc c 21

<210> 18
 <211> 24
 <212> DNA

<213> artificial sequence
<220>
<221> primer_bind
<223> primer 46f, specific for *ECa28SA2* gene
<400> 18

atatacttcc tacctaattgt ctca 24

<210> 19
<211> 20
<212> DNA
<213> artificial sequence
<220>
<221> primer_bind
<223> primer used for sequencing 28-kDa protein genes
in *E. canis*
<400> 19

agtgcagagt cttcggtttc 20

<210> 20
<211> 18
<212> DNA
<213> artificial sequence
<220>
<221> primer_bind
<223> primer used for sequencing 28-kDa protein genes
in *E. canis*
<400> 20

gttacttgcg gaggacat 18

<210> 21
<211> 24
<212> DNA
<213> artificial sequence
<220>
<221> primer_band
<222> nucleotides 687-710 of *ECa28-1*

<223> primer 394 for PCR

<400> 21

gcatttccac aggatcatag gtaa

24

<210> 22

<211> 24

<212> DNA

<213> artificial sequence

<220>

<221> primer_band

<222> nucleotides 710-687 of *ECa28-1*

<223> primer 394C for PCR

<400> 22

ttacctatga tcctgtggaa atgc

24

<210> 23

<211> 20

<212> DNA

<213> artificial sequence

<220>

<221> primer_bind

<223> primer 793C which anneals to a region with
Eca28-1, used to amplify the intergenic
region between gene *ECa28SA3* and *ECa28-1*

<400> 23

gagtaaccaa cagctcctgc

20

<210> 24

<211> 24

<212> DNA

<213> artificial sequence

<220>

<221> primer_band

<222>

<223> primer EC28OM-F complementary to noncoding
regions adjacent to the open reading frame

of *ECa28-1*

<400> 24

tctacttttgc acttccacta ttgt 24

<210> 25

<211> 24

<212> DNA

<213> artificial sequence

<220>

<221> primer_band

<223> primer EC28OM-R complementary to noncoding
regions adjacent to the open reading frame
of *ECa28-1*

<400> 25

attctttttgc cactattttt cttt 24

<210> 26

<211> 25

<212> DNA

<213> artificial sequence

<220>

<221> primer_bind

<223> primer *ECaSA3-2* corresponding to regions within
ECa28SA3, used to amplify the intergenic region
NC3 between gene *ECa28SA3* and *ECa28-1*

<400> 26

ctaggattag gttatagtat aagtt 25

<210> 27

<211> 23

<212> PRT

<213> *Ehrlichia canis*

<220>

<221> PEPTIDE

<223> a predicted N-terminal signal peptide of *ECa28-1*

and ECa28SA3

<400> 27

Met Asn Cys Lys Lys Ile Leu Ile Thr Thr Ala Leu Met Ser Leu
 5 10 15

Met Tyr Tyr Ala Pro Ser Ile Ser
 20

<210> 28

<211> 25

<212> PRT

<213> *Ehrlichia chaffeensis*

<220>

<223> amino acid sequence of N-terminal signal peptide
 of *E. chaffeensis* P28

<400> 28

Met Asn Tyr Lys Lys Ile Leu Ile Thr Ser Ala Leu Ile Ser Leu
 5 10 15

Ile Ser Ser Leu Pro Gly Val Ser Phe Ser
 20 25

<210> 29

<211> 26

<212> PRT

<213> *Ehrlichia canis*

<220>

<223> amino acid sequence of putative cleavage site of
 ECa28-1

<400> 29

Met Asn Cys Lys Lys Ile Leu Ile Thr Thr Ala Leu Ile Ser Leu
 5 10 15

Met Tyr Ser Ile Pro Ser Ile Ser Ser Phe Ser
 20 25

<210> 30

<211> 299

<212> DNA
<213> *Ehrlichia canis*
<220>
<223> nucleic acid sequence of intergenic noncoding
region 1 (28NC1)
<400> 30

taatactttct attgtacatg ttaaaaatag tactagtttg cttctgtggt 50
ttataaacgc aagagagaaa tagtttagtaa taaattagaa agttaaatat 100
tagaaaagtc atatgttttt cattgtcatt gatactcaac taaaagtagt 150
ataaatgtta cttattaata attttacgta gtatattaaa tttcccttac 200
aaaagccact agtattttat actaaaagct atactttggc ttgtatttaa 250
tttgtatttt tactactggt aatttacttt cactgtttct ggtgtaaat 299

<210> 31
<211> 345
<212> DNA
<213> *Ehrlichia canis*
<220>
<223> nucleic acid sequence of intergenic noncoding
region 2 (28NC2)
<400> 31

taatttcgtg gtacacatat cacgaagcta aaattgtttt tttatctctg 50
ctgtatacaa gagaaaaaat agtagtgaaa attacctaac aatatgacag 100
tacaagttta ccaagcttat ttcacaaaa cttcttgtgt cttttatctc 150
tttacaatga aatgtacact tagcttcact actgtagagt gtgtttatca 200
atgctttggt tattaatact ctacataata tgttaaattt ttcttacaaa 250
actcactagt aatttatact agaatatata ttctgacttg tatttgcttt 300
atacttccac tattgttaat ttattttcac tatttttaggt gtaat 345

<210> 32
<211> 345
<212> DNA
<213> *Ehrlichia canis*
<220>
<223> nucleic acid sequence of intergenic noncoding
region 3 (28NC3)
<400> 32

tgatatttatt gttgccacat attaaaaatg atctaaactt gttttttatta 50
ttgctacata caaaaaaaag aaaaatagtg gcaaaagaat gtagcaataa 100
gaggggggggg ggggactaaa tttaccttct attcttctaa tattctttac 150
tatattcaaa tagcacaact caatgcttcc aggaaaatat gtttctaata 200
ttttatttat taccaatcct tatataatat attaaatttc tcttacaaaa 250
atctctaatag ttttataactt aatatatata ttctggcttg tatttacttt 300
gcacttccac tattgttaat ttattttcac tatttttaggt gtaat 345

<210> 33

<211> 355

<212> DNA

<213> *Ehrlichia canis*

<220>

<223> nucleic acid sequence of intergenic noncoding
region 4 (28NC4)

<400> 33

taattttatt gttgccacat attaaaaatg atctaaactt gttttttawta 50
ttgctacata caaaaaaaga aaaatagtg gcaaaagaatg tagcaataag 100
agggggggggg gggaccaaatt ttatcttcta tgcttcccaa gtttttttcyc 150
gctatttatg acttaaacaa cagaaggtaa tatcctcacg gaaaacttat 200
cttcaaatat tttatttatt accaatctta tataatatat taaatttctc 250
ttacaaaaat cactagtatt ttataccaaa atatatttc tgacttgctt 300
ttcttctgca cttctactat ttttaattta tttgtcacta ttaggttata 350
ataaw 355